Differential gene expression in physiological and pathological angiogenesis

ABSTRACT

Methods of inhibiting pathological angiogenesis in a subject are disclosed. In particular examples, the method includes administering a therapeutically effective amount of a composition to a subject wherein the composition includes a specific binding agent that preferentially binds to one or more pathological angiogenesis marker proteins including Vscp, CD276, ETSvg4 (Pea3), CD137(4-1BB), MiRP2, Ubiquitin D (Fat10), Doppel (prion-PLP), Apelin, Plgf, Ptprn (IA-2), CD109, Ankylosis, and collagen VIIIα1. In additional examples, methods to deliver a therapeutic agent to a brain or liver endothelial cell are also disclosed.

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application No.60/858,068, filed on Nov. 9, 2006 and U.S. Provisional Application No.60/879,457, filed on Jan. 8, 2007, which are both incorporated herein byreference.

FIELD

The present disclosure relates to the field of angiogenesis andendothelial cell markers and in particular, to pathological angiogenesisendothelial markers and organ-specific endothelial markers and methodsof their uses.

BACKGROUND

Inhibition of tumor angiogenesis is an anticancer strategy that hasgained widespread support from biologists and clinicians. In 1971, Dr.Judah Folkman introduced the concept of an “angiogenic switch” drivingtumor growth and malignant progression. There have since been numerousscientific reports confirming the central concept that tumor growth isangiogenesis-dependent. Angiogenesis can occur under “normal”physiological conditions, such as during growth and development or woundhealing, as well as under “pathological” conditions, such as in thetransition of tumors from a dormant state to a malignant state. Thedependency of solid tumors on new vessel growth has made tumor vesselsan appealing target for cancer therapy.

Angiogenesis-based tumor therapy has several theoretical advantages overtraditional cancer therapies (such as radiation and chemotherapy).Anti-angiogenesis therapy targets endothelial cells that line tumorvessels instead of the tumor cells themselves. Tumor cells evolveresistance to cancer therapies due to genomic instability (highvariation) and rapid generation time (days). In contrast, endothelialcells have a higher genomic stability (low variation) and a longergeneration time (months) compared to tumor cells. Endothelial cells areless likely to “escape” therapy because they will not undergo mitosis atsuch a rapid rate and carry any drug resistance variation through to thenext generation within the lifespan of the therapy. Thus, the genomicstability of endothelial cells coupled with their longevity make them anattractive target for therapies directed against them.

Tumor endothelial markers (TEMs) were reported by St. Croix et al.(Science, 289: 1197-1201, 2000). St. Croix et al. employed serialanalysis of gene expression (SAGE™) technology to compare smallpopulations of normal and tumor-derived endothelial cells. Thecomparison revealed 79 genes that are potentially involved inangiogenesis. Of these, 46 genes were specifically expressed at leastten times higher in tumor-associated endothelium as compared to normalendothelium from the same patient.

The use of targeted drug delivery to inhibit tumor growth by interferingwith angiogenesis has recently proven to be successful. For example,bevacizumab (Avastin®), an antibody that neutralizes vascularendothelial growth factor (VEGF; one of the many proteins involved inthe development of a new network of blood vessels), has been approved bythe FDA to treat colorectal cancer. A remaining challenge, however, isto identify markers that can differentiate pathological andphysiological angiogenesis in order to selectively deliver therapeuticagents to diseased tissues while minimizing the potential side effectsof the targeted therapy.

SUMMARY

Disclosed herein are angiogenesis-specific endothelial markers,including some specific for pathological angiogenesis. Endothelial cellswere isolated from normal, regenerating, and tumor-bearing livers. Geneexpression profiles amongst the multiple samples were compared byperforming serial analysis of gene expression (SAGE) on the isolatedendothelial cells. The identification of markers highly specific forphysiological or pathological angiogenesis has significant implicationsfor the development of selective vascular targeted therapies. Thus,methods of reducing or inhibiting pathological angiogenesis in a subjectare disclosed.

In one example, the method includes administering a therapeuticallyeffective amount of a composition that includes one or more bindingagents (such as an antibody) that specifically binds to one or more ofthe following pathological angiogenesis marker proteins: Vscp, CD276,ETSvg4 (Pea3), CD137(4-1BB), MiRP2, Ubiquitin D (Fat10), Doppel(prion-PLP), Apelin, Plgf, Ptprn (IA-2), CD109, Ankylosis, and collagenVIIIα1, thereby inhibiting pathological angiogenesis in the subject. Ina further example, the binding agent is conjugated to one or moretherapeutic molecules, such as chemotherapy agents, cytoxins,radionucleotides or a combination thereof.

Methods are disclosed for screening for pathological angiogenesis in asubject. In particular examples, the method includes detecting at leastone expression product including one or more of: Vscp, CD276, ETSvg4(Pea3), CD137(4-1BB), MiRP2, Ubiquitin D (Fat10), Doppel (prion-PLP),Apelin, Plgf, Ptprn (IA-2), CD109, Ankylosis, and collagen VIII, 1 in asample obtained from the subject. Detection of the at least oneexpression product can indicate the presence of pathologicalangiogenesis in the subject.

In addition, disclosed herein are 27 brain-specific endothelial markersand 15 liver-specific endothelial markers. These organ-specificendothelial markers can serve as therapeutic targets to allow molecularagents to be selectively delivered to specific anatomical sites.Similarly, these organ-specific endothelial markers can serve asdiagnostic targets to allow diagnostic agents (such as imaging agents)to be selectively delivered to specific anatomical sites. Thus, methodsof delivering a therapeutic agent to organ-specific endothelial cellsare provided.

Methods are disclosed for delivering a therapeutic or diagnostic agentto brain endothelial cells. In particular examples, the method includesadministering a therapeutically effective amount of a composition thatincludes a therapeutic binding agent that preferentially binds to one ormore brain endothelial marker proteins. Such a method can evoke atherapeutic response in the brain endothelial cells or permit detectionof the cells. In certain cases brain endothelial markers may alsofacilitate the selectively delivery of therapeutic agents across theblood-brain barrier to underlying neuronal cells via transcytosis. Theone or more brain endothelial markers can include Glucose transporterGLUT-1, Organic anion transporter 2, Pleiotrophin, ATPase class V, type10A, Peptidoglycan recognition protein 1, Organic anion transporter 14,Forkhead box Q1, Organic anion transporter 3, SN2 (Solute carrier family38, member 5), Inter-alpha (globulin) inhibitor H5, Solute carrier 38member 3, Zinc finger protein of the cerebellum 2, Testican-2,3-HMG-CoAsynthase 2, Progestin and adipoQ receptor family member V, APCdown-regulated 1 Drapc1, GDPD phosphodiesterase family Accession No.NM_(—)001042671, putative transmembrane protein Accession No.NM_(—)029001, DES2 lipid desaturase/C4-hyroxylase, Kelch repeat and BTB(POZ) domain, Lipolysis stimulated receptor, Glutathione S-transferasealpha 4, TNF receptor superfamily member 19, T-box 1, putative secretedprotein Accession No. XM_(—)620023 or combinations thereof.

Methods are disclosed for delivering a therapeutic or diagnostic agentto liver endothelial cells. In particular examples, the method includesadministering a therapeutically effective amount of a composition thatincludes a binding agent that specifically binds to one or more liverendothelial marker proteins (e.g., deoxyribonuclease 1-like 3, LZPoncoprotein induced transcript 3, putative transmembrane proteinAccession No. NM_(—)023438, CD32 15, putative G-protein coupled receptorNM_(—)033616, C-type lectin-like receptor 2, C-type lectin domain family4 member g 16, Plexin C1, Wnt9B, Accession No. AK144596, GATA-bindingprotein 4, MBL-associated serine protease-3, Renin binding protein,putative transmembrane protein Accession No. NM_(—)144830, or Retinoicacid receptor, beta) and a therapeutic agent. Such a method can evoke atherapeutic response in the liver endothelial cells or permit detectionof the cells.

The foregoing and other features of the disclosure will become moreapparent from the following detailed description, which proceeds withreference to the accompanying figures.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1A includes digital images of heart tissue stained withimmunofluorescently-labeled CD105 (left panel), VE-cadherin (middlepanel) or both CD105 and VE-cadherin (right panel). Scale bar, 20 μm.

FIG. 1B is a digital image of liver tissue stained withimmunofluorescently-labeled CD105. Scale bar, 20 μm.

FIG. 1C is a bar graph showing the relative amount of VE-cadherindetected by quantitative polymerase chain reaction (QPCR) in cDNAisolated from unfractionated normal whole tissues (WT), purifiedendothelial cells (ECs) isolated from normal tissues (N-ECs) or purifiedECs isolated from tumors (T-ECs).

FIG. 1D is a schematic of a model used to identify genes expressedduring pathological, but not physiological angiogenesis. ECs wereisolated from normal resting livers, regenerating livers, or tumorbearing livers.

FIGS. 2A, 2B and 2C are bar graphs illustrating the expression ofvarious genes in resting normal ECs, regenerating liver ECs and tumorECs, respectively. The expression of the various genes was evaluated byreal-time Q-PCR and compared with that of Srnp70, a gene expressed atnearly identical levels in all ECs as detected by SAGE.

FIGS. 3A-31 are digital images of various mRNA expressed by ECs in vivodetected by staining samples with Oatp2 (a), CD276 (b), ETSvg4 (c),Apelin (d), CD109 (e), MiRP2 (f), CD137 (g), Doppel (h) and Vscp (i).(a) is representative of a brain endothelial marker in brain tissue, (b)and (c) depict HCT116 tumors grown subcutaneously, (d-f) depict SW620tumors grown subcutaneously, and (g-h) depict KM12 tumors grown in theliver. A dilute counterstain was applied to the sections to highlightthe lack of detectable expression in the non-ECs of the tumors. Scalebars, 50 μM.

FIG. 4A includes digital images of human colon samples stained withimmunoflurescently labeled CD276 and von Willebrand factor (vWF). CD276was expressed predominantly by the tumor vessels of the colorectalcancer, but was also expressed at a lower level by the tumor cellsthemselves. Expression of CD276 in normal colonic mucosa wasundetectable (top middle panel). As a control, vessels were stained forvWF, which co-localized with CD276 only in the tumor sample. Scale bar,100 μm.

FIG. 4B includes digital images of angiogenic vessels of the developingcorpus luteum stained with immunoflurescently-labeled CD276. CD276expression was undetectable in the angiogenic vessels of the developingcorpus luteum. Sections were counterstained with DAPI which is shown inthe left panels to highlight the epithelial cells. Scale bar, 200 μm.

FIG. 5 includes digital images of vessels of human colorectal cancer. Insitu hybridization revealed that CD276 mRNA is expressed predominantlyin the vessels of human colorectal cancer (middle panel) with a patternof staining similar to that of the control endothelial marker VEGFR2(left panel). In the case of CD276 the tumor cells also display positivestaining, albeit less intense. At the margin between tumor (T) tissueand normal (N) colonic mucosa CD276 staining abruptly ends (rightpanel). The extracellular staining around the normal crypts representsnon-specific binding of the in situ hybridization reagents to the mucous(right panel) and is also present in control sections. Scale bars, 50μM.

FIG. 6A is a digital image of an immunoblot including colorectal tumor(T) and normal (N) colonic mucosa samples. Immunoblotting with a CD276monoclonal antibody revealed an upregulation of CD276 protein incolorectal tumors (T) compared to normal (N) colonic mucosa.

FIG. 6B is a digital image of an immunoblot including lung tumor (T) andnormal (N) adjacent lung tissue samples. Immunoblotting with a CD276monoclonal antibody revealed an upregulation of CD276 protein in lungtumors (T) compared to normal (N) adjacent lung tissue. The normaltissues in A and B were classified as normal based on gross morphology,but microscopic disease or inflammatory host cells may have contributedto the low level CD276 expression observed in these tissues.

FIGS. 6C-6L are digital images of various samples stained with apolyclonal CD276 antibody. Immunohistochemical staining with apolyclonal CD276 antibody revealed a vessel-like pattern in colorectalcancer (C-E), non-small cell lung cancer (F-H), esophageal cancer (I-J),bladder cancer (K) and breast cancer (L). At the tumor margin (E) CD276staining was weak or undetectable in normal colonic mucosa (N) butstrong in the vessels of the adjacent tumor region (T). Vessels fromnormal tissues that failed to stain for CD276 were immunoreactive oncontrol serial sections stained for endothelial proteins such as vWF. Insome tumors, the vessels stained most prominently (C-E and H-K) whereasin others, both tumor cells and tumor vessels were strongly positive(F-G and L). A strong cell surface staining pattern in the tumorepithelium was detected under high power magnification (G). Many of theblood vessels were readily identified by the presence of blood cells inthe lumen; for example see inset displaying higher power magnificationof boxed region in (H). Sections were lightly counterstained withhematoxylin. Scale bar, 50 μM.

FIG. 7 is a digital image of amplification products generated in tumorcell lines or tumor endothelial cells in the presence of VE-cadherin,Ubiquitin D or β-actin primers. RT-PCR was used to verify that UbiquitinD is expressed by the tumor endothelial cells (TECs) and not the tumorcells themselves.

FIG. 8 is a digital image of an immunoblot including protein extractsfrom three subjects with either normal colonic mucosa (N) or colorectaltumors (T). CD137 expression was elevated in protein extracts of humancolorectal cancer.

FIG. 9A includes digital images of LEM and BEM genes identified by SAGEare expressed by ECs in vivo. Localization of mRNA in ECs wasdemonstrated for the brain endothelial markers GLUT-1 (BEM1) and organicanion transporter 2 (BEM2), and the liver endothelial markersdeoxyribonuclease 1-like 3 (LEM1) and oncogenes induced transcript 3(LEM2). The BEMs are selectively expressed in brain endothelium whereasthe LEMs are selectively expressed in liver endothelium. The endothelialcontrol probe, VEGFR2, stains both brain and liver endothelium. Stainingof LEMs is most prominent in the sinusoidal endothelium, wherein thenuclear body appears to stain most intensely. A dilute counterstain wasapplied to the sections to highlight the lack of detectable expressionin the non-ECs of the tissues. Scale bars, 50 μM

FIG. 9B includes digital images of localization of Apelin and DoppelmRNA in subcutaneous implanted LLC tumors.

DETAILED DESCRIPTION I. Introduction

Angiogenesis is critical for the progression of many diseases, includingage-related macular degeneration and cancer. Markers that candistinguish physiological and pathological angiogenesis are needed inorder to selectively deliver anti-angiogenic or vascular targetingagents to diseased tissues and minimize the potential side effects ofthe targeted therapy. Physiological and pathological angiogenesis aremorphologically distinct. However, the extent of differential geneexpression between these cellular states has remained elusive. Most ofthe well-studied molecules thought to regulate tumor angiogenesis, suchas vascular endothelial growth factor (VEGF), basic fibroblast growthfactor (bFGF), the angiopoietins, and their receptors, also regulatenormal physiological angiogenesis.

The inventors have identified twenty-five angiogenesis-specificendothelial markers, including thirteen that are specific forpathological angiogenesis. The genes specific for pathologicalangiogenesis were primarily cell surface molecules. Therefore, thisdisclosure provides several molecules that can be used for thetherapeutic targeting of tumor vessels. For example, a binding agentspecific to one or more of the disclosed pathological angiogenesisendothelial marker proteins can be used for targeted drug delivery tothe tumor site. Further, linking or conjugating the binding agent to achemical or radioactive toxin can provide a targeted cytotoxic therapy.In another or additional example, a binding agent specific to one ormore of the disclosed pathological angiogenesis endothelial markerproteins is labeled with an imaging tag, such as a fluorophore, therebyproviding diagnostic imaging agents.

Therefore, methods of reducing or inhibiting pathological angiogenesisare provided, in some examples a therapeutically effective amount of abinding agent that specifically binds to at least one of the disclosedpathological angiogenesis endothelial marker proteins is administered toa subject. As a result, pathological angiogenesis in the subject isthereby reduced or inhibited. Additional methods of diagnosing ortreating a tumor are also provided.

The present disclosure also provides twenty-seven brain-specificendothelial markers and fifteen liver-specific endothelial markers.These organ-specific endothelial markers can aid in the selectivedelivery of therapeutic and diagnostic agents to specific anatomicalsites. For example, methods are disclosed for delivering a therapeuticor diagnostic agent to brain endothelial cells. In particular examples,the method includes administering a therapeutically effective amount ofa binding agent, such as an antibody, that specifically binds to atleast one of the disclosed brain endothelial markers, thereby evoking atherapeutic response in the brain endothelial cells or permittingimaging of the brain endothelial cells. In another example, the bindingagent, upon binding at least one of the disclosed brain endothelialmarkers, would enable the delivery of the agent, via mechanisms such astranscytosis, across the blood-brain barrier to the particular cellsunderlying the brain endothelium, such as neuronal cells.

In a further example, the method includes delivering a therapeutic agentto liver endothelial cells by administering a therapeutically effectiveamount of a binding agent that specifically binds to at least one of thedisclosed liver endothelial marker proteins, thereby evoking atherapeutic response in the liver endothelial cells or permittingimaging of the liver endothelial cells.

II. Terms and Abbreviations Abbreviations

BEMs brain endothelial markers

cDNA: complementary DNA

ECs: endothelial cells

LEMs liver endothelial markers

μg: microgram

μl: microliter

M: molar

QPCR: quantitative PCR

PCR: polymerase chain reaction

SAGE: serial analysis of gene expression

The following explanations of terms and methods are provided to betterdescribe the present disclosure and to guide those of ordinary skill inthe art in the practice of the present disclosure. As used herein and inthe appended claims, the singular forms “a” or “an” or “the” includeplural references unless the context clearly dictates otherwise. Forexample, reference to “an endothelial marker” includes a plurality ofsuch markers and reference to “the antibody” includes reference to oneor more antibodies and equivalents thereof known to those skilled in theart, and so forth. The term “or” refers to a single element of statedalternative elements or a combination of two or more elements, unlessthe context clearly indicates otherwise. As used herein, “comprises”means “includes.” Thus, “comprising A or B,” means “including A, B, or Aand B,” without excluding additional elements.

Unless explained otherwise, all technical and scientific terms usedherein have the same meaning as commonly understood to one of ordinaryskill in the art to which this disclosure belongs.

Administration: To provide or give a subject an agent, such as acomposition that includes a binding agent that specifically binds to oneor more of the disclosed pathological angiogenesis endothelial markerproteins (such as those listed in Tables 8 and 9) by any effectiveroute. Exemplary routes of administration include, but are not limitedto, oral, injection (such as subcutaneous, intramuscular, intradermal,intraperitoneal, intravenous, and intratumoral), sublingual, rectal,transdermal, intranasal, vaginal and inhalation routes.

Agent: Any protein, nucleic acid molecule, compound, small molecule,organic compound, inorganic compound, or other molecule of interest.Agent can include a therapeutic agent, a diagnostic agent or apharmaceutical agent. A therapeutic or pharmaceutical agent is one thatalone or together with an additional compound induces the desiredresponse (such as inducing a therapeutic or prophylactic effect whenadministered to a subject). In a particular example, a pharmaceuticalagent (such as an antibody to any of the proteins listed in Tables 8 and9 conjugated to a therapeutic agent) significantly reduces angiogenesis.

Angiogenesis: A physiological process involving the growth of new bloodvessels from pre-existing vessels.

Angiogenesis can occur under normal physiological conditions such asduring growth and development or wound healing (known as physiologicalangiogenesis) as well as pathological conditions such as in thetransition of tumors from a dormant state to a malignant state (known aspathological angiogenesis).

Ankylosis: The ANK protein, the product of the progressive ankylosis(ank) gene, is a multipass transmembrane protein that is highlyconserved in vertebrates. The ANK protein has been shown to controlpyrophosphate levels in cells and may act as a pyrophosphate transporterthat stimulates the elaboration of extracellular pyrophosphate fromintracellular stores. The term ankylosis includes any ankylosis gene,cDNA, mRNA, or protein from any organism and that is ankylosis and isincreased during pathological angiogenesis relative to either normal orphysiological angiogenesis conditions. In one example, ANK protein isexpressed during pathological angiogenesis.

Exemplary nucleic acid and protein sequences for ankylosis are publiclyavailable. For example, GenBank Accession Nos.: DQ832285, NM_(—)020332,AK083135, BC054379, AY358503, and NM_(—)054027 disclose ankylosisnucleic acid sequences and GenBank Accession Nos.: AAF88038, Q9JHZ2,XP_(—)001132013, NP_(—)473368, and Q9HCJ1 disclose ankylosis proteinsequences.

In one example, ankylosis includes a full-length wild-type (or native)sequence, as well as ankylosis allelic variants, fragments, homologs orfusion sequences that retain the ability to be preferentially expressedduring pathological angiogenesis and/or modulate pathologicalangiogenesis. In certain examples, ankylosis has at least 80% sequenceidentity, for example at least 85%, 90%, 95%, or 98% sequence identityto ankylosis. In other examples, ankylosis has a sequence thathybridizes under very high stringency conditions to a sequence set forthin GenBank Accession No. DQ832285, NM_(—)020332, AK083135, BC054379,AY358503, or NM_(—)054027 and retains ankylosis activity (e.g., thecapability to be expressed during pathological angiogenesis and/ormodulate pathological angiogenesis).

Antibody: A polypeptide ligand including at least a light chain or heavychain immunoglobulin variable region which specifically recognizes andbinds an epitope of an antigen, such as an endothelial marker or afragment thereof. Antibodies are composed of a heavy and a light chain,each of which has a variable region, termed the variable heavy (V_(H))region and the variable light (V_(L)) region. Together, the V_(H) regionand the V_(L) region are responsible for binding the antigen recognizedby the antibody. In one example, an antibody specifically binds to oneof the proteins listed in Tables 8 and 9.

This includes intact immunoglobulins and the variants and portions ofthem well known in the art, such as Fab′ fragments, F(ab)′₂ fragments,single chain Fv proteins (“scFv”), and disulfide stabilized Fv proteins(“dsFv”). A scFv protein is a fusion protein in which a light chainvariable region of an immunoglobulin and a heavy chain variable regionof an immunoglobulin are bound by a linker, while in dsFvs, the chainshave been mutated to introduce a disulfide bond to stabilize theassociation of the chains. The term also includes genetically engineeredforms such as chimeric antibodies (for example, humanized murineantibodies), heteroconjugate antibodies (such as, bispecificantibodies). See also, Pierce Catalog and Handbook, 1994-1995 (PierceChemical Co., Rockford, Ill.); Kuby, J., Immunology, 3^(rd) Ed., W.H.Freeman & Co., New York, 1997.

Typically, a naturally occurring immunoglobulin has heavy (H) chains andlight (L) chains interconnected by disulfide bonds. There are two typesof light chain, lambda (λ) and kappa (k). There are five main heavychain classes (or isotypes) which determine the functional activity ofan antibody molecule: IgM, IgD, IgG, IgA and IgE.

Each heavy and light chain contains a constant region and a variableregion, (the regions are also known as “domains”). In combination, theheavy and the light chain variable regions specifically bind theantigen. Light and heavy chain variable regions contain a “framework”region interrupted by three hypervariable regions, also called“complementarity-determining regions” or “CDRs”. The extent of theframework region and CDRs have been defined (see, Kabat et al.,Sequences of Proteins of Immunological Interest, U.S. Department ofHealth and Human Services, 1991, which is hereby incorporated byreference). The Kabat database is now maintained online. The sequencesof the framework regions of different light or heavy chains arerelatively conserved within a species. The framework region of anantibody, that is the combined framework regions of the constituentlight and heavy chains, serves to position and align the CDRs inthree-dimensional space.

The CDRs are primarily responsible for binding to an epitope of anantigen. The CDRs of each chain are typically referred to as CDR1, CDR2,and CDR3, numbered sequentially starting from the N-terminus, and arealso typically identified by the chain in which the particular CDR islocated. Thus, a V_(H) CDR3 is located in the variable domain of theheavy chain of the antibody in which it is found, whereas a V_(L) CDR1is the CDR1 from the variable domain of the light chain of the antibodyin which it is found. An antibody that binds RET will have a specificV_(H) region and the V_(L) region sequence, and thus specific CDRsequences. Antibodies with different specificities (i.e. differentcombining sites for different antigens) have different CDRs. Although itis the CDRs that vary from antibody to antibody, only a limited numberof amino acid positions within the CDRs are directly involved in antigenbinding. These positions within the CDRs are called specificitydetermining residues (SDRs).

References to “V_(H)” or “VH” refer to the variable region of animmunoglobulin heavy chain, including that of an Fv, scFv, dsFv or Fab.References to “V_(L)” or “VL” refer to the variable region of animmunoglobulin light chain, including that of an Fv, scFv, dsFv or Fab.

A “monoclonal antibody” is an antibody produced by a single clone ofB-lymphocytes or by a cell into which the light and heavy chain genes ofa single antibody have been transfected. Monoclonal antibodies areproduced by methods known to those of skill in the art, for instance bymaking hybrid antibody-forming cells from a fusion of myeloma cells withimmune spleen cells. Monoclonal antibodies include humanized monoclonalantibodies.

A “polyclonal antibody” is an antibody that is derived from differentB-cell lines. Polyclonal antibodies are a mixture of immunoglobulinmolecules secreted against a specific antigen, each recognising adifferent epitope. These antibodies are produced by methods known tothose of skill in the art, for instance, by injection of an antigen intoa suitable mammal (such as a mouse, rabbit or goat) that induces theB-lymphocytes to produce IgG immunoglobulins specific for the antigenwhich are then purified from the mammal's serum.

A “chimeric antibody” has framework residues from one species, such ashuman, and CDRs (which generally confer antigen binding) from anotherspecies, such as a murine antibody that specifically binds anendothelial marker.

A “humanized” immunoglobulin is an immunoglobulin including a humanframework region and one or more CDRs from a non-human (for example amouse, rat, or synthetic) immunoglobulin. The non-human immunoglobulinproviding the CDRs is termed a “donor,” and the human immunoglobulinproviding the framework is termed an “acceptor.” In one embodiment, allthe CDRs are from the donor immunoglobulin in a humanizedimmunoglobulin. Constant regions need not be present, but if they are,they are substantially identical to human immunoglobulin constantregions, e.g., at least about 85-90%, such as about 95% or moreidentical. Hence, all parts of a humanized immunoglobulin, exceptpossibly the CDRs, are substantially identical to corresponding parts ofnatural human immunoglobulin sequences. Humanized immunoglobulins can beconstructed by means of genetic engineering (see for example, U.S. Pat.No. 5,585,089).

Binding affinity: Affinity of one molecule for another, such as anantibody for an antigen (for example, the antigens shown in Tables 8 and9). In one example, affinity is calculated by a modification of theScatchard method described by Frankel et al., Mol. Immunol., 16:101-106,1979. In another example, binding affinity is measured by anantigen/antibody dissociation rate. In yet another example, a highbinding affinity is measured by a competition radioimmunoassay. Inseveral examples, a high binding affinity is at least about 1×10⁻⁸ M. Inother examples, a high binding affinity is at least about 1.5×10⁻⁸, atleast about 2.0×10⁻⁸, at least about 2.5×10⁻⁸, at least about 3.0×10⁻⁸,at least about 3.5×10⁻⁸, at least about 4.0×10⁻⁸, at least about4.5×10⁻⁸, or at least about 5.0×10⁻⁸ M.

Biological activity: An expression describing the beneficial or adverseeffects of an agent on living matter. When the agent is a complexchemical mixture, this activity is exerted by the substance's activeingredient or pharmacophore, but can be modified by the otherconstituents. Activity is generally dosage-dependent and it is notuncommon to have effects ranging from beneficial to adverse for onesubstance when going from low to high doses. In one example, a specificbinding agent significantly reduces the biological activity of the oneor more pathological angiogenesis marker proteins (such as those listedin Table 9) which in turn inhibits pathological angiogenesis.

Cancer: Malignant neoplasm that has undergone characteristic anaplasiawith loss of differentiation, increase rate of growth, invasion ofsurrounding tissue, and is capable of metastasis.

CD276: A member of the B7 family of immunoregulatory molecules that canbe induced on T-cells, macrophages and dendritic cells by a variety ofinflammatory cytokines. Its homology to other co-stimulatory moleculesindicates it may have an immunoregulatory role. In particular examples,expression of CD276 is increased during pathological angiogenesis. Theterm CD276 includes any CD276 gene, cDNA, mRNA, or protein from anyorganism and that is CD276 and is expressed during pathologicalangiogenesis.

Nucleic acid and protein sequences for CD276 are publicly available. Forexample, GenBank Accession Nos.: DQ832276, NM_(—)001024736, AK031354,AK155114, NM_(—)133983, and NM_(—)025240 disclose CD276 nucleic acidsequences, and GenBank Accession Nos.: NP_(—)598744, NP_(—)079516, andAAK15438 disclose CD276 protein sequences.

In one example, CD276 includes a full-length wild-type (or native)sequence, as well as CD276 allelic variants, fragments, homologs orfusion sequences that retain the ability to be expressed duringpathological angiogenesis and/or modulate pathological angiogenesis. Incertain examples, CD276 has at least 80% sequence identity, for exampleat least 85%, 90%, 95%, or 98% sequence identity to CD276. In otherexamples, CD276 has a sequence that hybridizes under very highstringency conditions to a sequence set forth in GenBank Accession No.DQ832276, NM_(—)001024736, NP_(—)598744, NP_(—)079516 and AAK15438, orNM_(—)025240 and retains CD276 activity (such as the capability to beexpressed during pathological angiogenesis and/or modulate pathologicalangiogenesis).

Chemotherapy: In cancer treatment, chemotherapy refers to theadministration of one or a combination of compounds to kill or slow thereproduction of rapidly multiplying cells. Chemotherapuetic agentsinclude but are not limited to: 5-fluorouracil (5-FU), azathioprine,cyclophosphamide, antimetabolites (such as Fludarabine), antineoplastics(such as Etoposide, Doxorubicin, methotrexate, and Vincristine),carboplatin, cis-platinum and the taxanes, such as taxol and taxotere.Such agents can be co-administered with the disclosed endothelial markermolecules to a subject. For example, to treat a tumor, chemotherapeuticagents can also be administered prior to or subsequent to administrationof the disclosed modified endothelial marker molecules to a subject orcan be conjugated to the disclosed endothelial markers (e.g., Tables 8and 9). In one example, chemotherapeutic agents are co-administered withradiation therapy, along with the disclosed endothelial molecules fortreatment of a tumor.

Chimeric antibody: An antibody which includes sequences derived from twodifferent antibodies, which typically are of different species. Mosttypically, chimeric antibodies include human and murine antibodydomains, generally human constant regions and murine variable regions,murine CDRs and/or murine SDRs. For example, the variable segments ofthe genes from a mouse monoclonal antibody can be joined to humanconstant segments, such as kappa and gamma 1 or gamma 3. In one example,a chimeric antibody is a hybrid protein composed of the variable orantigen-binding domain from a mouse antibody and the constant oreffector domain from a human antibody (such as an antibody thatrecognizes one of the disclosed pathological angiogenesis endothelialmarkers listed in Table 9), although other mammalian species can beused, or the variable region can be produced by molecular techniques.Methods of making chimeric antibodies are well known in the art, forexample, see U.S. Pat. No. 5,807,715.

Decrease: To reduce the quality, amount, or strength of something. Inone example, a therapy decreases a tumor (such as the size of a tumor,the number of tumors, the metastasis of a tumor, or combinationsthereof), or one or more symptoms associated with a tumor, for exampleas compared to the response in the absence of the therapy (such as atherapy administered to affect tumor size by inhibiting pathologicalangiogenesis via administration of a binding agent capable of binding toone or more of the pathological angiogenesis markers listed in Table 9).In a particular example, a therapy decreases the size of a tumor, thenumber of tumors, the metastasis of a tumor, or combinations thereof,subsequent to the therapy, such as a decrease of at least 10%, at least20%, at least 50%, or even at least 90%. Such decreases can be measuredusing the methods disclosed herein as well as those known in the art.

Endothelial cell: Cells that line the interior surface of blood vessels,forming an interface between circulating blood in the lumen and the restof the vessel wall. For example, endothelial cells line the entirecirculatory system. Further, both blood and lymphatic capillaries arecomposed of a single layer of endothelial cells.

Expression product with Accession No. AK144596: In one example, AK144596is a protein that is expressed in liver endothelial cells. The termexpression product with Accession No. AK144596 includes any expressionproduct with Accession No. AK144596 gene, cDNA, mRNA, or protein fromany organism and that is an expression product with Accession No.AK144596 capable of delivering a therapeutic agent specifically to liverendothelial cells.

Nucleic acid and protein sequences for expression product with AccessionNo. AK144596 are publicly available. For example, GenBank Accession No:AK144596 discloses an expression product with Accession No. AK144596nucleic acid sequence.

In one example, an expression product with Accession No. AK144596includes a full-length wild-type (or native) sequence, as well as anexpression product with Accession No. AK144596 allelic variants,fragments, homologs or fusion sequences that retain the ability todeliver therapeutic agents specifically to liver endothelial cells. Incertain examples, an expression product with Accession No. AK144596 hasat least 80% sequence identity, for example at least 85%, 90%, 95%, or98% sequence identity to an expression product with Accession No.AK144596. In other examples, an expression product with Accession No.AK144596 has a sequence that hybridizes under very high stringencyconditions to a sequence set forth in GenBank Accession No. AK144596 andretains expression product with Accession No. AK144596 activity (e.g.,the capability to serve as a liver endothelial cell marker).

Forkhead box Q1 (FOXQ1): A member of the evolutionarily conserved wingedhelix (WH)/forkhead transcription factor gene family. The proteinregulates the expression of other genes. In one example, FOXQ1 proteinis expressed in brain endothelial cells. The term FOXQ1 includes anyFOXQ1 gene, cDNA, mRNA, or protein from any organism and that is FOXQ1capable of delivering a therapeutic agent specifically to brainendothelial cells.

Nucleic acid and protein sequences for FOXQ1 are publicly available. Forexample, GenBank Accession Nos.: NM_(—)008239, AK147202, AF010405,AF225950, and NM_(—)033260 disclose FOXQ1 nucleic acid sequences andGenBank Accession Nos.: NP_(—)032265, AAH53850, and NP_(—)150285disclose FOXQ1 protein sequences.

In one example, FOXQ1 includes a full-length wild-type (or native)sequence, as well as FOXQ1 allelic variants, fragments, homologs orfusion sequences that retain the ability to deliver therapeutic agentsspecifically to brain endothelial cells. In certain examples, FOXQ1 hasat least 80% sequence identity, for example at least 85%, 90%, 95%, or98% sequence identity to FOXQ1. In other examples, FOXQ1 has a sequencethat hybridizes under very high stringency conditions to a sequence setforth in GenBank Accession Nos. NM_(—)008239, AK147202, AF010405,AF225950, or NM_(—)033260 and retains FOXQ1 (e.g., the capability toserve as a brain endothelial cell marker).

Humanized antibodies: An immunoglobulin including a human frameworkregion and one or more CDRs from a non-human (such as a mouse, rat, orsynthetic) immunoglobulin. A humanized antibody binds to the sameantigen as the donor antibody that provides the CDRs. In on example, ahumanized antibody specifically binds to one of the proteins listed inTables 8 and 9.

The non-human immunoglobulin providing the CDRs is termed a “donor” andthe human immunoglobulin providing the framework is termed an“acceptor.” In one example, all the CDRs are from the donorimmunoglobulin in a humanized immunoglobulin. Constant regions need notbe present, but if they are, they are substantially identical to humanimmunoglobulin constant regions, for instance, at least about 85-90%,such as about 95% or more identical.

The donor CDRs of a humanized antibody can have a limited number ofsubstitutions using amino acids from the acceptor CDR. Hence, all partsof a humanized immunoglobulin, except possibly the CDRs, aresubstantially identical to corresponding parts of natural humanimmunoglobulin sequences. The acceptor framework of a humanizedimmunoglobulin or antibody can have a limited number of substitutions byamino acids taken from the donor framework. Humanized or othermonoclonal antibodies can have additional amino acid substitutions whichhave substantially no effect on antigen binding or other immunoglobulinfunctions. Exemplary conservative substitutions are described above (seealso U.S. Pat. No. 5,585,089). Humanized immunoglobulins can beconstructed by means of genetic engineering, for example, see U.S. Pat.Nos. 5,225,539 and 5,585,089, herein incorporated by reference.

Hybridization: To form base pairs between complementary regions of twostrands of DNA, RNA, or between DNA and RNA, thereby forming a duplexmolecule. Hybridization conditions resulting in particular degrees ofstringency will vary depending upon the nature of the hybridizationmethod and the composition and length of the hybridizing nucleic acidsequences. Generally, the temperature of hybridization and the ionicstrength (such as the Na+ concentration) of the hybridization bufferwill determine the stringency of hybridization. Calculations regardinghybridization conditions for attaining particular degrees of stringencyare discussed in Sambrook et al., (1989) Molecular Cloning, secondedition, Cold Spring Harbor Laboratory, Plainview, N.Y. (chapters 9 and11). The following is an exemplary set of hybridization conditions andis not limiting:

Very High Stringency (detects sequences that share at least 90%identity)

Hybridization: 5×SSC at 65° C. for 16 hours

Wash twice: 2×SSC at room temperature (RT) for 15 minutes each

Wash twice: 0.5×SSC at 65° C. for 20 minutes each

High Stringency (detects sequences that share at least 80% identity)

Hybridization: 5×-6×SSC at 65° C.-70° C. for 16-20 hours

Wash twice: 2×SSC at RT for 5-20 minutes each

Wash twice: 1×SSC at 55° C.-70° C. for 30 minutes each

Low Stringency (detects sequences that share at least 50% identity)

Hybridization: 6×SSC at RT to 55° C. for 16-20 hours

Wash at least twice: 2×-3×SSC at RT to 55° C. for 20-30 minutes each.

Immunoassay: A biochemical test that measures the level of a substancein a biological sample (such as serum or urine), using the reaction ofan antibody or antibodies to its antigen. The assay takes advantage ofthe specific binding of an antibody to its antigen. The antibodiesselected ideally have a high affinity for the antigen (if there isantigen available, a very high proportion of it will bind to theantibody). Both the presence of antigen or antibodies can be measured.For instance, when detecting pathological angiogenesis the presence of apathological angiogenesis marker can be measured.

Detecting the quantity of antibody or antigen can be achieved by avariety of methods. One of the most common is to label the antigen orantibody. The label can include an enzyme (e.g., luciferase or β-gal),radioisotopes (such as ¹²⁵I) or a fluorophore. Other techniques includeWestern Blot.

Kelch repeat and BTB (POZ) domain: In one example, the Kelch repeat andBTB (POZ) domain is expressed in brain endothelial cells. The term Kelchrepeat and BTB (POZ) domain includes any Kelch repeat and BTB (POZ)domain gene, cDNA, mRNA, or protein from any organism and that is Kelchrepeat and BTB (POZ) domain capable of delivering a therapeutic agentspecifically to brain endothelial cells.

Nucleic acid and protein sequences for Kelch repeat and BTB (POZ) domainare publicly available. For example, GenBank Accession Nos.:XM_(—)486083, XM_(—)979486, XM_(—)921147, NM_(—)014867, and AB018254disclose Kelch repeat and BTB (POZ) domain nucleic acid sequences andGenBank Accession Nos.: XP_(—)926240, XP_(—)486083, and NP_(—)055682disclose ankylosis protein sequences.

In one example, Kelch repeat and BTB (POZ) domain includes a full-lengthwild-type (or native) sequence, as well as Kelch repeat and BTB (POZ)domain allelic variants, fragments, homologs or fusion sequences thatretain the ability to deliver therapeutic agents specifically to brainendothelial cells. In certain examples, Kelch repeat and BTB (POZ)domain has at least 80% sequence identity, for example at least 85%,90%, 95%, or 98% sequence identity to Kelch repeat and BTB (POZ) domain.In other examples, Kelch repeat and BTB (POZ) domain has a sequence thathybridizes under very high stringency conditions to a sequence set forthin GenBank Accession Nos. XM_(—)486083, XM_(—)486083, XM_(—)979486,XM_(—)921147, NM_(—)014867, or AB018254 and retains Kelch repeat and BTB(POZ) domain activity (e.g., the capability to deliver therapeuticagents to brain endothelial cells).

Label: A detectable compound. In some examples, a label is conjugateddirectly or indirectly to another molecule, such as an antibody or aprotein, to facilitate detection of that molecule. For example, thelabel can be capable of detection by ELISA, spectrophotometry, flowcytometry, or microscopy. Specific, non-limiting examples of labelsinclude fluorophores, chemiluminescent agents, enzymatic linkages, andradioactive isotopes. Methods for labeling and guidance in the choice oflabels appropriate for various purposes are discussed for example inSambrook et al. (Molecular Cloning: A Laboratory Manual, Cold SpringHarbor, N.Y., 1989) and Ausubel et al. (In Current Protocols inMolecular Biology, John Wiley & Sons, New York, 1998). In a particularexample, a label is conjugated to a binding agent that specificallybinds to one or more of the pathological angiogenesis endothelialmarkers disclosed in Table 9 to allow for the detection/screening forpathological angiogenesis and/or the presence of a tumor in a subject.

Malignant: Cells that have the properties of anaplasia invasion andmetastasis.

Mammal: This term includes both human and non-human mammals. Examples ofmammals include, but are not limited to: humans, pigs, cows, goats,cats, dogs, rabbits and mice.

MBL-associated serine protease-3 (MASP-3): MASP-3 transcripts encodeserine proteases that display distinct substrate specificity andassociate with Mannan-binding lectin complexes. In one example,MBL-associated serine protease-3 is preferentially expressed in liverendothelial cells. The term MBL-associated serine protease-3 includesany MBL-associated serine protease-3 gene, cDNA, mRNA, or protein fromany organism and that is a MBL-associated serine protease-3 capable ofdelivering a therapeutic agent specifically to liver endothelial cells.

Exemplary nucleic acid and protein sequences for MBL-associated serineprotease-3 are publicly available. For example, GenBank Accession Nos.:AB049755, AK031598, NM_(—)139125, NM_(—)001879, and NM_(—)001031849disclose MBL-associated serine protease-3 nucleic acid sequences andGenBank Accession Nos.: NP 624302, NP_(—)001870, and NP_(—)001027019disclose MBL-associated serine protease-3 protein sequences.

In one example, a MBL-associated serine protease-3 sequence includes afull-length wild-type (or native) sequence, as well as MBL-associatedserine protease-3 allelic variants, fragments, homologs or fusionsequences that retain the ability to deliver therapeutic agentsspecifically to liver endothelial cells. In certain examples,MBL-associated serine protease-3 has at least 80% sequence identity, forexample at least 85%, 90%, 95%, or 98% sequence identity to aMBL-associated serine protease-3. In other examples, a MBL-associatedserine protease-3 has a sequence that hybridizes under very highstringency conditions to a sequence set forth in GenBank Accession No.AB049755, AB049755, AK031598, NM_(—)139125, NM_(—)001879, orNM_(—)001031849 and retains MBL-associated serine protease-3 activity(e.g., the capability to deliver therapeutic agents to liver endothelialcells).

MiRP2: The MiRP2 gene encodes a small integral membrane subunit thatassembles with HERG, a pore-forming protein, to form a potassiumvoltage-gated channel. MiRP2 alters the function of the channel.Channels formed with mutant MiRP1 subunits display slower activation,faster deactivation, and increased drug sensitivity.

In one example, MiRP2 is expressed during pathological angiogenesis. Theterm MiRP2 includes any MiRP2 gene, cDNA, mRNA, or protein from anyorganism and that is MiRP2 and is expressed during pathologicalangiogenesis.

Exemplary nucleic acid and protein sequences for MiRP2 are publiclyavailable. For example, GenBank Accession Nos.: DQ832280, NM_(—)020574,AK008744, and NM_(—)005472 disclose MiRP2 nucleic acid sequences andGenBank Accession Nos.: NP_(—)065599, BAB25871, and NP_(—)005463disclose MiRP2 protein sequences.

In one example, MiRP2 includes a full-length wild-type (or native)sequence, as well as MiRP2 allelic variants, fragments, homologs orfusion sequences that retain the ability to be expressed duringpathological angiogenesis and/or modulate pathological angiogenesis. Incertain examples, MiRP2 has at least 80% sequence identity, for exampleat least 85%, 90%, 95%, or 98% sequence identity to MiRP2. In otherexamples, MiRP2 has a sequence that hybridizes under very highstringency conditions to a sequence set forth in GenBank Accession Nos.DQ832280, NM_(—)020574, AK008744, or NM_(—)005472 and retains MiRP2activity (e.g., the capability to be expressed during pathologicalangiogenesis and/or modulate pathological angiogenesis).

Neoplasm: Abnormal growth of cells.

Normal Cell: Non-tumor cell, non-malignant, uninfected cell.

Oncoprotein induced transcript 3 (Oit3): Encodes a secreted ZPdomain-containing protein. In one example, oncoprotein inducedtranscript 3 is expressed in liver endothelial cells. The termoncoprotein induced transcript 3 includes any oncoprotein inducedtranscript 3 gene, cDNA, mRNA, or protein from any organism and that isa oncoprotein induced transcript 3 capable of delivering a therapeuticagent specifically to liver endothelial cells. Oncoprotein inducedtranscript 3 is also referred to in the literature as LZP.

Oncoprotein induced transcript 3 nucleic acid and protein sequences arepublicly available. For example, GenBank Accession Nos.: NM_(—)010959,AF356506, AY180915, NM_(—)152635, and AY013707 disclose oncoproteininduced transcript 3 nucleic acid sequences and GenBank Accession Nos.:AAO22058, NP_(—)035089, NP_(—)689848, and AAG40096 disclose oncoproteininduced transcript 3 protein sequences.

In one example, a oncoprotein induced transcript 3 sequence includes afull-length wild-type (or native) sequence, as well as oncoproteininduced transcript 3 allelic variants, fragments, homologs or fusionsequences that retain the ability to deliver therapeutic agentsspecifically to liver endothelial cells. In certain examples,oncoprotein induced transcript 3 has at least 80% sequence identity, forexample at least 85%, 90%, 95%, or 98% sequence identity to a nativeoncoprotein induced transcript 3. In other examples, oncoprotein inducedtranscript 3 has a sequence that hybridizes under very high stringencyconditions to a sequence set forth in GenBank Accession Nos.NM_(—)010959, AF356506, AY180915, NM_(—)152635, or AY013707 and retainsoncoprotein induced transcript 3 activity.

Pharmaceutically Carriers The pharmaceutically acceptable carriers(vehicles) useful in this disclosure are conventional. Remington'sPharmaceutical Sciences, by E. W. Martin, Mack Publishing Co., Easton,Pa., 15th Edition (1975), describes compositions and formulationssuitable for pharmaceutical delivery of one or more therapeutic agents,such as one or more compositions that include a binding agent thatspecifically binds to at least one of the disclosed pathologicalangiogenesis marker proteins.

In general, the nature of the carrier will depend on the particular modeof administration being employed. For instance, parenteral formulationscan include injectable fluids that include pharmaceutically andphysiologically acceptable fluids such as water, physiological saline,balanced salt solutions, aqueous dextrose, glycerol or the like as avehicle. In addition to biologically-neutral carriers, pharmaceuticalcompositions to be administered can contain minor amounts of non-toxicauxiliary substances, such as wetting or emulsifying agents,preservatives, and pH buffering agents and the like, for example sodiumacetate or sorbitan monolaurate, sodium lactate, potassium chloride,calcium chloride, and triethanolamine oleate.

Plexin C1 (VESPR): A large transmembrane receptor. In vitro, plexin-C1has been shown to bind the GPI-anchored semaphorin Sema7A and thesoluble viral semaphorins SemaVA (A39R) and SemaVB (AHV). Plexin C1engagement by SemaVA inhibits integrin-mediated dendritic cell adhesionand chemotaxis in vitro, suggesting a role for plexin C1 in dendriticcell migration.

In an example, plexin C1 is expressed in liver endothelial cells. Theterm plexin C1 includes any plexin C1 gene, cDNA, mRNA, or protein fromany organism and that is a plexin C1 capable of delivering a therapeuticagent specifically to liver endothelial cells.

Exemplary nucleic acid and protein sequences for plexin C1 are publiclyavailable. For example, GenBank Accession Nos.: NM_(—)018797,XM_(—)622776, AB208934, and NM_(—)005761 disclose plexin C1 nucleic acidsequences and GenBank Accession Nos.: NP_(—)061267, XP_(—)622776,BAD92171, and NP_(—)005752 disclose plexin C1 protein sequences.

In one example, a plexin C1 sequence includes a full-length wild-type(or native) sequence, as well as plexin C1 allelic variants, fragments,homologs or fusion sequences that retain the ability to delivertherapeutic agents specifically to liver endothelial cells. In certainexamples, plexin C1 has at least 80% sequence identity, for example atleast 85%, 90%, 95%, or 98% sequence identity to a plexin C1. In otherexamples, a plexin C1 has a sequence that hybridizes under very highstringency conditions to a sequence set forth in GenBank Accession No.NM_(—)018797, XM_(—)622776, AB208934, or NM_(—)005761 and retains plexinC1 activity (e.g., the capability to deliver therapeutic agents to liverendothelial cells).

Polymerase Chain Reaction (PCR): An in vitro amplification techniquethat increases the number of copies of a nucleic acid molecule (forexample, a nucleic acid molecule in a sample or specimen). In anexample, a biological sample collected from a subject is contacted witha pair of oligonucleotide primers, under conditions that allow for thehybridization of the primers to nucleic acid template in the sample. Theprimers are extended under suitable conditions, dissociated from thetemplate, and then re-annealed, extended, and dissociated to amplify thenumber of copies of the nucleic acid. The product of a PCR can becharacterized by electrophoresis, restriction endonuclease cleavagepatterns, oligonucleotide hybridization or ligation, and/or nucleic acidsequencing, using standard techniques.

Preimplantation protein 4 (Prei4): The Prei4 gene is expressed duringmouse preimplantation embryogenesis. It is a putativeglycerophosphodiester phosphodiesterase. In one example, Prei4 isexpressed in brain endothelial cells. The term Prei4 includes any Prei4gene, cDNA, mRNA, or protein from any organism and that is Prei4 capableof delivering a therapeutic agent specifically to brain endothelialcells.

Nucleic acid and protein sequences for Prei4 are publicly available. Forexample, GenBank Accession Nos.: NM_(—)001042671, NM_(—)028802,BC006887, and NM_(—)019593 disclose Prei4 nucleic acid sequences andGenBank Accession Nos.: NP_(—)001036136, NP_(—)062539, and Q9NPB8disclose Prei4 protein sequences.

In one example, Prei4 includes a full-length wild-type (or native)sequence, as well as Prei4 allelic variants, fragments, homologs orfusion sequences that retain the ability to deliver therapeutic agentsspecifically to brain endothelial cells. In certain examples, Prei4 hasat least 80% sequence identity, for example at least 85%, 90%, 95%, or98% sequence identity to Prei4. In other examples, Prei4 has a sequencethat hybridizes under very high stringency conditions to a sequence setforth in GenBank Accession Nos. NM_(—)001042671, NM_(—)028802, BC006887,or NM_(—)019593 and retains Prei4 activity (e.g., the capability todeliver therapeutic agents to brain endothelial cells).

Probes and primers: Nucleic acid probes and primers can be readilyprepared based on the nucleic acid molecules provided in thisdisclosure. A probe includes an isolated nucleic acid attached to adetectable label or reporter molecule. Exemplary labels includeradioactive isotopes, enzyme substrates, co-factors, ligands,chemiluminescent or fluorescent agents, haptens, and enzymes.

Primers are short nucleic acid molecules such as DNA oligonucleotides,10 nucleotides or more in length. Longer DNA oligonucleotides can beabout 15, 17, 20, or 23 nucleotides or more in length. Primers can beannealed to a complementary target DNA strand by nucleic acidhybridization to form a hybrid between the primer and the target DNAstrand, and then the primer extended along the target DNA strand by aDNA polymerase enzyme. Primer pairs can be used for amplification of anucleic acid sequence, e.g., by the polymerase chain reaction (PCR) orother nucleic-acid amplification methods known in the art.

Methods for preparing and using probes and primers are described, forexample, in Sambrook et al. (In Molecular Cloning: A Laboratory Manual,CSHL, New York, 1989), Ausubel et al. (In Current Protocols in MolecularBiology, Greene Publ. Assoc. and Wiley-Intersciences, 1998), and Inniset al. (PCR Protocols, A Guide to Methods and Applications, AcademicPress, Inc., San Diego, Calif., 1990). PCR primer pairs can be derivedfrom a known sequence, for example, by using computer programs intendedfor that purpose such as Primer (Version 0.5, (© 1991, WhiteheadInstitute for Biomedical Research, Cambridge, Mass.).

Progestin and adipoQ receptor family member V (Paqr5): An integralmembrane protein that binds progesterone. Paqr5 is a putative G-proteincoupled receptor involved in signal transduction in response to steroidssuch as progesterone.

In one example, Paqr5 is expressed in brain endothelial cells. The termProgestin and adipoQ receptor family member V includes any Progestin andadipoQ receptor family member V gene, cDNA, mRNA, or protein from anyorganism and that is Progestin and adipoQ receptor family member Vcapable of delivering a therapeutic agent specifically to brainendothelial cells.

Exemplary nucleic acid and protein sequences for Progestin and adipoQreceptor family member V are publicly available. For example, GenBankAccession Nos: NM_(—)028748, AK035475, AY424283, and NM_(—)017705disclose Progestin and adipoQ receptor family member V nucleic acidsequences and GenBank Accession Nos.: NP_(—)083024, BAC29072, AAR08371,and NP_(—)060175 disclose Progestin and adipoQ protein sequences.

In one example, Progestin and adipoQ receptor family member V includes afull-length wild-type (or native) sequence, as well as Progestin andadipoQ receptor family member V allelic variants, fragments, homologs orfusion sequences that retain the ability to deliver therapeutic agentsspecifically to brain endothelial cells. In certain examples, Progestinand adipoQ receptor family member V has at least 80% sequence identity,for example at least 85%, 90%, 95%, or 98% sequence identity toProgestin and adipoQ receptor family member V. In other examples,Progestin and adipoQ receptor family member V has a sequence thathybridizes under very high stringency conditions to a sequence set forthin GenBank Accession Nos. NM_(—)028748, NM_(—)028748, AK035475,AY424283, or NM_(—)017705 and retains Progestin and adipoQ receptorfamily member V activity (e.g., the capability to deliver therapeuticagents to brain endothelial cells).

Ptprn (IA-2): PTPRN (IA-2) is a major autoantigen in type 1 diabetes.Autoantibodies against PTPRN appear years before the development ofclinical disease. PTPRN is an enzymatically inactive member of thetransmembrane protein tyrosine phosphatase family and is an integralcomponent of secretory granules in neuroendocrine cells. PTPRN is animportant regulator of dense core vesicle number and glucose-induced andbasal insulin secretion.

In one example, Ptprn is expressed during pathological angiogenesis. Theterm Ptprn includes any Ptprn gene, cDNA, mRNA, or protein from anyorganism and that is Ptprn and is preferentially expressed duringpathological angiogenesis. Ptprn is also known in the literature asIA-2.

Exemplary nucleic acid and protein sequences for Ptprn are publiclyavailable. For example, GenBank Accession Nos.: DQ832283, NM_(—)008985,AK041296, NM_(—)002846, and L18983 disclose Ptprn nucleic acid sequencesand GenBank Accession Nos.: NP_(—)033011, NP_(—)002837, and AAA90974disclose Ptprn (IA-2) protein sequences.

In one example, Ptprn includes a full-length wild-type (or native)sequence, as well as Ptprn allelic variants, fragments, homologs orfusion sequences that retain the ability to be preferentially expressedduring pathological angiogenesis and/or modulate pathologicalangiogenesis. In certain examples, Ptprn has at least 80% sequenceidentity, for example at least 85%, 90%, 95%, or 98% sequence identityto Ptprn. In other examples, Ptprn has a sequence that hybridizes undervery high stringency conditions to a sequence set forth in GenBankAccession Nos. DQ832283, NM_(—)008985, AK041296, NM_(—)002846, or L18983and retains Ptprn activity (e.g., the capability to be expressed duringpathological angiogenesis and/or modulate pathological angiogenesis).

Putative G-protein coupled receptor NM_(—)033616 or Component ofSp100-rs (Csprs): A putative G-protein coupled receptor. In one example,putative G-protein coupled receptor NM_(—)033616 is expressed in liverendothelial cells. The term putative G-protein coupled receptorNM_(—)033616 includes any putative G-protein coupled receptorNM_(—)033616 gene, cDNA, mRNA, or protein from any organism and that isa putative G-protein coupled receptor NM_(—)033616 capable of deliveringa therapeutic agent specifically to liver endothelial cells.

Exemplary nucleic acid and protein sequences for putative G-proteincoupled receptor NM_(—)033616 are publicly available. For example,GenBank Accession Nos.: NM_(—)033616, AK037063, and XM_(—)979370disclose putative G-protein coupled receptor NM_(—)033616 nucleic acidsequences and GenBank Accession Nos.: NP_(—)291094 and XP_(—)984464disclose putative G-protein coupled receptor NM_(—)033616 proteinsequences.

In one example, a putative G-protein coupled receptor NM_(—)033616sequence includes a full-length wild-type (or native) sequence, as wellas putative G-protein coupled receptor NM_(—)033616 allelic variants,fragments, homologs or fusion sequences that retain the ability todeliver therapeutic agents specifically to liver endothelial cells. Incertain examples, putative G-protein coupled receptor NM_(—)033616 hasat least 80% sequence identity, for example at least 85%, 90%, 95%, or98% sequence identity to a putative G-protein coupled receptorNM_(—)033616. In other examples, a putative G-protein coupled receptorNM_(—)033616 has a sequence that hybridizes under very high stringencyconditions to a sequence set forth in GenBank Accession Nos.NM_(—)033616, AK037063, or XM_(—)979370 and retains putative G-proteincoupled receptor NM_(—)033616 activity (e.g., the capability to targetagents to liver endothelial cells).

Putative transmembrane protein Accession No. NM_(—)023438: A putativetransmembrane protein. In one example, putative transmembrane proteinAccession No. NM_(—)023438 is expressed in liver endothelial cells. Theterm putative transmembrane protein Accession No. NM_(—)023438 includesany putative transmembrane protein Accession No. NM_(—)023438 gene,cDNA, mRNA, or protein from any organism and that is a putativetransmembrane protein Accession No. NM_(—)023438 capable of delivering atherapeutic agent specifically to liver endothelial cells.

Exemplary nucleic acid and protein sequences for putative transmembraneprotein Accession No. NM_(—)023438 are publicly available. For example,GenBank Accession Nos.: NM_(—)023438, NM_(—)207313, and BN000149disclose putative transmembrane protein Accession No. NM_(—)023438nucleic acid sequences and GenBank Accession Nos.: NP_(—)075927,NP_(—)997196, and CAD80169 disclose putative transmembrane proteinAccession No. NM_(—)023438 protein sequences.

In one example, a putative transmembrane protein Accession No.NM_(—)023438 sequence includes a full-length wild-type (or native)sequence, as well as putative transmembrane protein Accession No.NM_(—)023438 allelic variants, fragments, homologs or fusion sequencesthat retain the ability to deliver therapeutic agents specifically toliver endothelial cells. In certain examples, putative transmembraneprotein Accession No. NM_(—)023438 has at least 80% sequence identity,for example at least 85%, 90%, 95%, or 98% sequence identity to aputative transmembrane protein Accession No. NM_(—)023438. In otherexamples, a putative transmembrane protein Accession No. NM_(—)023438has a sequence that hybridizes under very high stringency conditions toa sequence set forth in GenBank Accession Nos. NM_(—)023438,NM_(—)207313, and BN000149 and retains putative transmembrane proteinAccession No. NM_(—)023438 activity (e.g., the capability to targetagents to liver endothelial cells).

Putative transmembrane protein Accession No. NM_(—)029001: A putativetransmembrane protein. In one example, putative transmembrane proteinAccession No. NM_(—)029001 is expressed in brain endothelial cells. Theterm putative transmembrane protein Accession No. NM_(—)029001 includesany putative transmembrane protein Accession No. NM_(—)029001 gene,cDNA, mRNA, or protein from any organism and that is a putativetransmembrane protein Accession No. NM_(—)029001 capable of delivering atherapeutic agent specifically to brain endothelial cells.

Exemplary nucleic acid and protein sequences for putative transmembraneprotein Accession No. NM_(—)029001 are publicly available. For example,GenBank Accession Nos.: NM_(—)029001, NM_(—)024930, and AB181393disclose putative transmembrane protein Accession No. NM_(—)029001nucleic acid sequences and GenBank Accession Nos.: NP_(—)083277,NP_(—)079206, and BAD93238 disclose putative transmembrane proteinAccession No. NM_(—)029001 protein sequences.

In one example, a putative transmembrane protein Accession No.NM_(—)029001 sequence includes a full-length wild-type (or native)sequence, as well as putative transmembrane protein Accession No.NM_(—)029001 allelic variants, fragments, homologs or fusion sequencesthat retain the ability to deliver therapeutic agents specifically tobrain endothelial cells. In certain examples, putative transmembraneprotein Accession No. NM_(—)029001 has at least 80% sequence identity,for example at least 85%, 90%, 95%, or 98% sequence identity to aputative transmembrane protein Accession No. NM_(—)029001. In otherexamples, a putative transmembrane protein Accession No. NM_(—)029001has a sequence that hybridizes under very high stringency conditions toa sequence set forth in GenBank Accession No. NM_(—)029001,NM_(—)024930, or AB181393 and retains putative transmembrane proteinAccession No. NM_(—)029001 activity (e.g., the capability to targetagents to brain endothelial cells).

Putative transmembrane protein Accession No. NM_(—)144830:

NM_(—)144830 encodes a putative transmembrane protein. In one example,putative transmembrane protein Accession No. NM_(—)144830 is expressedin liver endothelial cells. The term putative transmembrane proteinAccession No. NM_(—)144830 includes any putative transmembrane proteinAccession No. NM_(—)144830 gene, cDNA, mRNA, or protein from anyorganism and that is putative transmembrane protein Accession No.NM_(—)144830 capable of delivering a therapeutic agent specifically toliver endothelial cells.

Exemplary nucleic acid and protein sequences for putative transmembraneprotein Accession No. NM_(—)144830 are publicly available. For example,GenBank Accession Nos.: NM_(—)144830, AK154217, NM_(—)145041, andXM_(—)001133074 disclose putative transmembrane protein Accession No.NM_(—)144830 nucleic acid sequence and GenBank Accession Nos.:NP_(—)659079, BAE32441, NP_(—)659478, and XP_(—)001133074 discloseputative transmembrane protein Accession No. NM_(—)144830 proteinsequences.

In one example, putative transmembrane protein Accession No.NM_(—)144830 includes a full-length wild-type (or native) sequence, aswell as putative transmembrane protein Accession No. NM_(—)144830allelic variants, fragments, homologs or fusion sequences that retainthe ability to deliver therapeutic agents specifically to liverendothelial cells. In certain examples, putative transmembrane proteinAccession No. NM_(—)144830 has at least 80% sequence identity, forexample at least 85%, 90%, 95%, or 98% sequence identity to putativetransmembrane protein Accession No. NM_(—)144830. In other examples,putative transmembrane protein Accession No. NM_(—)144830 has a sequencethat hybridizes under very high stringency conditions to a sequence setforth in GenBank Accession No. NM_(—)144830, AK154217, NM_(—)145041, orXM_(—)001133074 and retains putative transmembrane protein Accession No.NM_(—)144830 activity (e.g., the capability to target agents to liverendothelial cells).

Putative secreted protein Accession No. XM_(—)620023: XM_(—)620023encodes a putative secreted protein. In one example, putative secretedprotein Accession No. XM_(—)620023 is expressed in brain endothelialcells. The term putative secreted protein Accession No. NM_(—)620023includes any putative secreted protein Accession No. XM_(—)620023 gene,cDNA, mRNA, or protein from any organism and that is a putative secretedprotein Accession No. NM_(—)620023 capable of delivering a therapeuticagent specifically to brain endothelial cells.

Exemplary nucleic acid and protein sequences for putative secretedprotein Accession No. XM_(—)620023 are publicly available. For example,GenBank Accession Nos.: XM_(—)620023, AK128180, and BX648118 disclosesecreted protein Accession No. XM_(—)620023 nucleic acid sequences andGenBank Accession Nos.: XP_(—)620023, BAC87313, and CAH56187 discloseputative secreted protein Accession No. XM_(—)620023 protein sequences.

In one example, a putative secreted protein Accession No. XM_(—)620023sequence includes a full-length wild-type (or native) sequence, as wellas putative secreted protein Accession No. XM_(—)620023 allelicvariants, fragments, homologs or fusion sequences that retain theability to deliver therapeutic agents specifically to brain endothelialcells. In certain examples, putative secreted protein Accession No.XM_(—)620023 has at least 80% sequence identity, for example at least85%, 90%, 95%, or 98% sequence identity to a putative secreted proteinAccession No. XM_(—)620023. In other examples, a putative secretedprotein Accession No. XM_(—)620023 has a sequence that hybridizes undervery high stringency conditions to a sequence set forth in GenBankAccession Nos. XM_(—)620023, BAC87313, and CAH56187 and retains putativesecreted protein Accession No. NM_(—)620023 activity (e.g., thecapability to target agents to brain endothelial cells).

Sample: Biological specimens containing genomic DNA, cDNA, RNA, orprotein obtained from the cells of a subject, such as those present inperipheral blood, urine, saliva, semen, tissue biopsy, surgicalspecimen, fine needle aspriates, amniocentesis samples and autopsymaterial. In one example, a sample includes lung, colon, breast or livercancer cells obtained from a subject.

Sequence identity: The identity/similarity between two or more nucleicacid sequences, or two or more amino acid sequences, is expressed interms of the identity or similarity between the sequences. Sequenceidentity can be measured in terms of percentage identity; the higher thepercentage, the more identical the sequences are. Sequence similaritycan be measured in terms of percentage similarity (which takes intoaccount conservative amino acid substitutions); the higher thepercentage, the more similar the sequences are. Homologs or orthologs ofnucleic acid or amino acid sequences possess a relatively high degree ofsequence identity/similarity when aligned using standard methods. Thishomology is more significant when the orthologous proteins or cDNAs arederived from species that are more closely related (such as human andmouse sequences), compared to species more distantly related (such ashuman and C. elegans sequences).

Methods of alignment of sequences for comparison are well known in theart. Various programs and alignment algorithms are described in: Smith &Waterman, Adv. Appl. Math. 2:482, 1981; Needleman & Wunsch, J. Mol.Biol. 48:443, 1970; Pearson & Lipman, Proc. Natl. Acad. Sci. USA85:2444, 1988; Higgins & Sharp, Gene, 73:237-44, 1988; Higgins & Sharp,CABIOS 5:151-3, 1989; Corpet et al., Nuc. Acids Res. 16:10881-90, 1988;Huang et al. Computer Appls. in the Biosciences 8, 155-65, 1992; andPearson et al., Meth. Mol. Bio. 24:307-31, 1994. Altschul et al., J.Mol. Biol. 215:403-10, 1990, presents a detailed consideration ofsequence alignment methods and homology calculations.

The NCBI Basic Local Alignment Search Tool (BLAST) (Altschul et al., J.Mol. Biol. 215:403-10, 1990) is available from several sources,including the National Center for Biological Information (NCBI, NationalLibrary of Medicine, Building 38A, Room 8N805, Bethesda, Md. 20894) andon the Internet, for use in connection with the sequence analysisprograms blastp, blastn, blastx, tblastn and tblastx. Additionalinformation can be found at the NCBI web site.

BLASTN is used to compare nucleic acid sequences, while BLASTP is usedto compare amino acid sequences. To compare two nucleic acid sequences,the options can be set as follows: -i is set to a file containing thefirst nucleic acid sequence to be compared (such as C:\seq1.txt); -j isset to a file containing the second nucleic acid sequence to be compared(such as C:\seq2.txt); -p is set to blastn; -o is set to any desiredfile name (such as C:\output.txt); -q is set to −1; -r is set to 2; andall other options are left at their default setting. For example, thefollowing command can be used to generate an output file containing acomparison between two sequences: C:\B12seq-i c:\seq1.txt-jc:\seq2.txt-p blastn-o c:\output.txt-q−1-r 2.

To compare two amino acid sequences, the options of B12seq can be set asfollows: -i is set to a file containing the first amino acid sequence tobe compared (such as C:\seq1.txt); -j is set to a file containing thesecond amino acid sequence to be compared (such as C:\seq2.txt); -p isset to blastp; -o is set to any desired file name (such asC:\output.txt); and all other options are left at their default setting.For example, the following command can be used to generate an outputfile containing a comparison between two amino acid sequences:C:\B12seq-i c:\seq1.txt-j c:\seq2.txt-p blastp-o c:\output.txt. If thetwo compared sequences share homology, then the designated output filewill present those regions of homology as aligned sequences. If the twocompared sequences do not share homology, then the designated outputfile will not present aligned sequences.

Once aligned, the number of matches is determined by counting the numberof positions where an identical nucleotide or amino acid residue ispresented in both sequences. The percent sequence identity is determinedby dividing the number of matches either by the length of the sequenceset forth in the identified sequence, or by an articulated length (suchas 100 consecutive nucleotides or amino acid residues from a sequenceset forth in an identified sequence), followed by multiplying theresulting value by 100. For example, a nucleic acid sequence that has1166 matches when aligned with a test sequence having 1154 nucleotidesis 75.0 percent identical to the test sequence (1166÷1554*100=75.0). Thepercent sequence identity value is rounded to the nearest tenth. Forexample, 75.11, 75.12, 75.13, and 75.14 are rounded down to 75.1, while75.15, 75.16, 75.17, 75.18, and 75.19 are rounded up to 75.2. The lengthvalue will always be an integer. In another example, a target sequencecontaining a 20-nucleotide region that aligns with 20 consecutivenucleotides from an identified sequence as follows contains a regionthat shares 75 percent sequence identity to that identified sequence(15÷20*100=75).

For comparisons of amino acid sequences of greater than about 30 aminoacids, the Blast 2 sequences function is employed using the defaultBLOSUM62 matrix set to default parameters, (gap existence cost of 11,and a per residue gap cost of 1). Homologs are typically characterizedby possession of at least 70% sequence identity counted over thefull-length alignment with an amino acid sequence using the NCBI BasicBlast 2.0, gapped blastp with databases such as the nr or swissprotdatabase. Queries searched with the blastn program are filtered withDUST (Hancock and Armstrong Comput. Appl. Biosci. 10: 67-70, 1994).Other programs use SEG. In addition, a manual alignment can beperformed. Proteins with even greater similarity will show increasingpercentage identities when assessed by this method, such as at least75%, 80%, 85%, 90%, 95%, or 99% sequence identity to any protein listedin Tables 8 and 9.

When aligning short peptides (fewer than around 30 amino acids), thealignment should be performed using the Blast 2 sequences function,employing the PAM30 matrix set to default parameters (open gap 9,extension gap 1 penalties). Proteins with even greater similarity to thereference sequence will show increasing percentage identities whenassessed by this method, such as at least 60%, 70%, 75%, 80%, 85%, 90%,95%, 98%, or 99% sequence identity. When less than the entire sequenceis being compared for sequence identity, homologs will typically possessat least 75% sequence identity over short windows of 10-20 amino acids,and can possess sequence identities of at least 85%, 90%, 95% or 98%depending on their identity to the reference sequence. Methods fordetermining sequence identity over such short windows are described atthe NCBI web site.

One indication that two nucleic acid molecules are closely related isthat the two molecules hybridize to each other under stringentconditions. Stringent conditions are sequence-dependent and aredifferent under different environmental parameters. Nucleic acidsequences that do not show a high degree of identity may neverthelessencode identical or similar (conserved) amino acid sequences, due to thedegeneracy of the genetic code. Changes in a nucleic acid sequence canbe made using this degeneracy to produce multiple nucleic acid moleculesthat all encode substantially the same protein. Such homologous nucleicacid sequences can, for example, possess at least 60%, 70%, 80%, 90%,95%, 98%, or 99% sequence identity determined by this method. Inparticular, homologous nucleic acid sequences can possess at least 60%,70%, 80%, 90%, 95%, 98% or 99% sequence identity to the nucleic acidsequences that encode endothelial cell proteins listed in Tables 8 and9. In a further example, homologous proteins can possess at least 60%,70%, 80%, 90%, 95%, 98% or 99% sequence identity to the endothelial cellproteins listed in Tables 8 and 9.

One of skill in the art will appreciate that these sequence identityranges are provided for guidance only; it is possible that stronglysignificant homologs could be obtained that fall outside the rangesprovided.

An alternative (and not necessarily cumulative) indication that twonucleic acid sequences are substantially identical is that thepolypeptide which the first nucleic acid encodes is immunologicallycross reactive with the polypeptide encoded by the second nucleic acid.

Serial analysis of gene expression (SAGE): A technique that can be usedto characterize gene expression, or more precisely gene transcription.Briefly, the SAGE approach is a method for the rapid quantitative andqualitative analysis of mRNA transcripts based upon the isolation andanalysis of short defined sequence tags (SAGE Tags) corresponding toexpressed genes. Each Tag is a short nucleotide sequence (such as 9-33base pairs in length) from a defined position in the transcript. In theSAGE method, the Tags are dimerized to reduce bias inherent in cloningor amplification reactions (See, U.S. Pat. No. 5,695,937). SAGE isparticularly suited to the characterization of genes associated withvasculature stimulation or inhibition because it is capable of detectingrare sequence, evaluating large numbers of sequences at one time, and toprovide a basis for the identification of previously unknown genes.

Specific Binding Agent: An agent that binds substantially only to adefined target such as a protein, enzyme, polysaccharide,oligonucleotide, DNA, RNA, recombinant vector or a small molecule. Thus,a protein-specific binding agent binds substantially only the definedprotein, or to a specific region within the protein. In an example, a“specific binding agent” includes antibodies and other agents that bindsubstantially to a specified polypeptide. Exemplary antibodies includemonoclonal or polyclonal antibodies that are specific for thepolypeptide, as well as immunologically effective portions (“fragments”)thereof. In an example, a “specific binding agent” is capable of bindingto at least one of the disclosed physiological or pathologicalangiogenesis endothelial marker proteins. For instance, the “specificbinding agent” is an antibody specific for at least one of the disclosedphysiological or pathological angiogenesis endothelial marker proteins.In an additional example, the “specific binding agent” is capable ofinteracting with at least one of the organ-specific endothelial markerproteins.

The determination that a particular agent binds substantially only to aspecific polypeptide may readily be made by using or adapting routineprocedures. One suitable in vitro assay makes use of the Westernblotting procedure (described in many standard texts, including Harlowand Lane, Using Antibodies: A Laboratory Manual, CSHL, New York, 1999).In further examples, the specific binding agent is capable of binding toa mRNA or small molecule that results in pathological angiogenesis beinginhibited.

Subject: Living multicellular vertebrate organisms, a category whichincludes both human and veterinary subjects that are in need of thedesired biological effect, such as treatment of a tumor. Examplesinclude, but are not limited to: humans, apes, dogs, cats, mice, rats,rabbits, horses, pigs, and cows.

Therapeutically Effective Amount: An amount of a composition that alone,or together with an additional therapeutic agent(s) (for example achemotherapeutic agent), induces the desired response (e.g., treatmentof a tumor). The preparations disclosed herein are administered intherapeutically effective amounts.

In one example, a desired response is to decrease tumor size ormetastasis in a subject to whom the therapy is administered. Tumormetastasis does not need to be completely eliminated for the compositionto be effective. For example, a composition can decrease metastasis by adesired amount, for example by at least 20%, at least 50%, at least 60%,at least 70%, at least 80%, at least 90%, at least 95%, at least 98%, oreven at least 100% (elimination of the tumor), as compared to metastasisin the absence of the composition.

In particular examples, it is an amount of the therapeutic agentconjugated to the specific binding agent effective to decrease a numberof cancer cells, such as in a subject to whom it is administered, forexample a subject having one or more carcinomas. The cancer cells do notneed to be completely eliminated for the composition to be effective.For example, a composition can decrease the number of cancer cells by adesired amount, for example by at least 20%, at least 50%, at least 60%,at least 70%, at least 80%, at least 90%, at least 95%, at least 98%, oreven at least 100% (elimination of detectable cancer cells), as comparedto the number of cancer cells in the absence of the composition.

In other examples, it is an amount of the specific binding agent for oneor more of the disclosed pathological angiogenesis protein markerscapable of reducing pathological angiogenesis by least 20%, at least50%, at least 60%, at least 70%, at least 80%, at least 90%, at least95%, at least 98%, or even at least 100% (elimination of detectablepathological angiogenesis) by the specific binding agent, or both,effective to decrease the metastasis of a tumor.

A therapeutically effective amount of a specific binding agent for atleast one of the disclosed pathological angiogenesis protein markers, orcancer cells lysed by a therapeutic molecule conjugated to the agent,can be administered in a single dose, or in several doses, for exampledaily, during a course of treatment. However, the therapeuticallyeffective amount can depend on the subject being treated, the severityand type of the condition being treated, and the manner ofadministration. For example, a therapeutically effective amount of suchagent can vary from about 1 μg-10 mg per 70 kg body weight ifadministered intravenously and about 10 μg -100 mg per 70 kg body weightif administered intratumorally.

Treating a disease: “Treatment” refers to a therapeutic interventionthat ameliorates a sign or symptom of a disease or pathologicalcondition, such a sign or symptom of a tumor. Treatment can also induceremission or cure of a condition, such as a tumor. In particularexamples, treatment includes preventing a disease, for example byinhibiting the full development of a disease, such as preventingdevelopment of a tumor (such as a metastasis). Prevention of a diseasedoes not require a total absence of a tumor. For example, a decrease ofat least 50% can be sufficient.

Tumor: A neoplasm. Includes solid and hematological (or liquid) tumors.Examples of solid tumors, such as sarcomas and carcinomas, include, butare not limited to: fibrosarcoma, myxosarcoma, liposarcoma,chondrosarcoma, osteogenic sarcoma, and other sarcomas, synovioma,mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, coloncarcinoma, lymphoid malignancy, pancreatic cancer, breast cancer, lungcancers, ovarian cancer, prostate cancer, hepatocellular carcinoma,squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweatgland carcinoma, sebaceous gland carcinoma, papillary carcinoma,papillary adenocarcinomas, medullary carcinoma, bronchogenic carcinoma,renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma,Wilms' tumor, cervical cancer, testicular tumor, bladder carcinoma, andCNS tumors (such as a glioma, astrocytoma, medulloblastoma,craniopharyogioma, ependymoma, pinealoma, hemangioblastoma, acousticneuroma, oligodendroglioma, menangioma, melanoma, neuroblastoma andretinoblastoma).

Unit dose: A physically discrete unit containing a predeterminedquantity of an active material calculated to individually orcollectively produce a desired effect, such as a therapeutic effect. Asingle unit dose or a plurality of unit doses can be used to provide thedesired effect, such as treatment of a tumor, for example a metastatictumor. In one example, a unit dose includes a desired amount of an agentthat decreases or inhibits pathological angiogenesis.

Vscp: Encodes an SH2-containing protein. In one example, Vscp isexpressed during pathological angiogenesis. The term Vscp includes anyVscp gene, cDNA, mRNA, or protein from any organism and that is Vscp andis expressed during pathological angiogenesis.

Exemplary nucleic acid and protein sequences for Vscp are publiclyavailable. For example, GenBank Accession Nos.: DQ832275, XM_(—)357399,AK032598, XM_(—)375698, and XM_(—)939275 disclose Vscp nucleic acidsequences and GenBank Accession Nos.: XP_(—)357399, XP_(—)375698, andXP_(—)944368 disclose Vscp protein sequences.

In one example, Vscp includes a full-length wild-type (or native)sequence, as well as Vscp allelic variants, fragments, homologs orfusion sequences that retain the ability to be expressed duringpathological angiogenesis and/or modulate pathological angiogenesis. Incertain examples, Vscp has at least 80% sequence identity, for exampleat least 85%, 90%, 95%, or 98% sequence identity to Vscp. In otherexamples, Vscp has a sequence that hybridizes under very high stringencyconditions to a sequence set forth in GenBank Accession No. DQ832275,XM_(—)357399, AK032598, XM_(—)375698, and XM_(—)939275 and retains Vscpactivity (e.g., the capability to be expressed during pathologicalangiogenesis and/or modulate pathological angiogenesis).

Western blot: A method in molecular biology/biochemistry/immunogeneticsto detect protein in a biological sample, such as a tissue homogenate orextract. Gel electrophoresis can be employed to separate denaturedproteins by mass. Following separation, the proteins are transferred outof the gel and onto a membrane (typically nitrocellulose), where theyare “probed” using antibodies specific to the protein. As a result, theamount of protein in the sample can be examined and compared to otherprotein levels. Other techniques also using antibodies allow detectionof proteins in tissues (immunohistochemistry) and cells(immunocytochemistry).

Additional terms commonly used in molecular genetics can be found inBenjamin Lewin, Genes V published by Oxford University Press, 1994 (ISBN0-19-854287-9); Kendrew et al (eds.), The Encyclopedia of MolecularBiology, published by Blackwell Science Ltd., 1994 (ISBN 0-632-02182-9);and Robert A. Meyers (ed.), Molecular Biology and Biotechnology: aComprehensive Desk Reference, published by VCH Publishers, Inc., 1995(ISBN 1-56081-569-8).

Methods of Treatment

It is shown herein that pathological angiogenesis is associated with theincreased expression of at least thirteen endothelial cell proteins(such as the pathological angiogenesis marker proteins listed in Table9). It is also demonstrated that these proteins are not increased duringphysiological angiogenesis. In addition, expression levels of variousendothelial cell proteins have been found to be dependent upon the organin which the proteins are expressed. Based on these observations,methods of treating pathological angiogenesis, such as pathologicalangiogenesis associated with a tumor, are disclosed. Further, methods ofdelivering a therapeutic agent to a specific organ to treat a diseaseare disclosed.

Methods are disclosed herein for treating pathological angiogenesis,such as that associated with a tumor. In one example, the methodincludes administering a therapeutically effective amount of acomposition to a subject in which the composition includes a specificbinding agent that preferentially binds to one or more pathologicalangiogenesis marker proteins listed in Table 9 or a subset thereof, suchas at least 1, at least 2, at least 3, at least 5, at least 10, or atleast 12 (for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, or 13 ofthose listed). In particular examples, the one or more pathologicalangiogenesis marker proteins are Vscp, CD276, MiRP2, Ptprn (IA-2),ankylosis or combinations thereof. The specific binding agent can be anantibody to one or more of the pathological angiogenesis marker proteinsconjugated to a therapeutic molecule, such as a cytotoxin,chemotherapeutic reagent, radionucleotide or a combination thereof.

Inhibiting Pathological Angiogenesis

Pathological angiogenesis is a physiological process involving thegrowth of new blood vessels under pathological conditions. For example,pathological angiogenesis is involved in the transition of tumors from adormant state to a malignant state. Inhibition of pathologicalangiogenesis does not require 100% inhibition, but can include at leasta reduction (such as a reduction of at least 10% or at least 25%) if nota complete inhibition of new blood vessels associated with a specificpathological condition.

In an example, inhibiting pathological angiogenesis can be used to treata tumor. Treatment of a tumor by reducing new blood vessel growth caninclude preventing or delaying the development of the tumor in a subject(such as preventing metastasis of a tumor), and also includes reducingsigns or symptoms associated with the presence of such a tumor (forexample by reducing the size or volume of the tumor or a metastasisthereof). Such reduced growth can in some examples decrease or slowmetastasis of the tumor, or reduce the size or volume of the tumor by atleast 10%, at least 20%, at least 50%, or at least 75%. For example,pathological angiogenesis can be inhibited to treat cancer such as aliver, breast, colon and lung cancer. In another example, inhibition ofpathological angiogenesis includes reducing the invasive activity of thetumor in the subject, for example by reducing the ability of the tumorto metastasize by reducing or inhibiting new blood vessel growth. Insome examples, treatment using the methods disclosed herein prolongs thetime of survival of the subject.

Specific Binding Agents

Specific binding agents are agents that bind with higher affinity to amolecule of interest, than to other molecules. For example, a specificbinding agent can be one that binds with high affinity to one of theproteins listed in Tables 8 and 9, but does not substantially bind toanother protein. In a specific example, a specific binding agent bindsto one of the proteins listed in Tables 8 and 9 with a binding affinityin the range of 0.1 to 20 nM.

Examples of specific binding agents include antibodies, ligands,recombinant proteins, peptide mimetics, and soluble receptor fragments.One specific example of a specific binding agent is an antibody, such asa monoclonal or polyclonal antibody. Methods of making antibodies thatcan be used clinically are known in the art. Particular antibodies andmethods that can be used to produce them are described in detail below.

Another specific example of a specific binding agent is a cell surfacereceptor ligand. Many cell surface receptors have natural ligands thatoften bind the receptors with high affinity. The ligands, that can beeither soluble or cell surface bound, can be used to direct cytotoxicagents to tumors. For example, VEGF has been fused to the toxin geloninand used in preclinical models to prevent the growth of several tumortypes. In an example, the ligand is cell surface receptor itself and arecombinant protein including the extracellular portion of the ligandcan be used as a specific binding agent. For instance, the extracellulardomain can be fused to a toxin or labeled with an agent that allowsdetection of the tumor endothelium. In a particular example, the cellsurface ligand 4-1BBL can be used as a specific binding agent for CD137.In other examples, the ligand for CD276 or CD109 can be used.

In a further example, small molecular weight inhibitors or antagonistsof the receptor protein can be used to regulate pathologicalangiogenesis. In a particular example, small molecular weight inhibitorsor antagonists of the MiRP2 protein are used to inhibit pathologicalangiogenesis.

In other specific examples, the function of secreted proteins thatparticipate in angiogenesis may be altered by using antibodies thatrecognize the secreted proteins, or soluble recombinant receptorfragments. An example of this is bevacizumab (Avastin), a monoclonalantibody that recognizes VEGF which has been approved by the FDA for thetreatment of human metastatic colorectal cancer and non-small cell lungcancer. The VEGF-trap is a receptor fusion protein that also binds toand blocks VEGF and is also currently in clinical development.

Specific binding agents can be therapeutic, for example by reducing orinhibiting the biological activity of a protein. For example, a specificbinding agent that binds with high affinity to one of the proteinslisted in Tables 8 and 9, may substantially reduce the biologicalfunction of the protein (for example, the ability of the protein topromote pathological angiogenesis). In other examples, a specificbinding agent is conjugated to a therapeutic molecule, for example ananti-tumor agent. In this way, the specific binding agent permitstargeting of the therapeutic molecule to the cells of interest, such asvascular endothelium. Such agents can be administered in therapeuticallyeffective amounts to individuals in need thereof, such as a subjecthaving a tumor.

Therapeutic Molecules

Therapeutic molecules include agents that can be used to treat adisease, such as a tumor. In a specific example, a therapeutic moleculeis one that alone or together with an additional compound induces thedesired therapeutic response. One or more therapeutic molecules can beconjugated directly or indirectly to a specific binding agent, such asan antibody that binds to one of the proteins listed in Tables 8 and 9.For example, an antibody that binds to CD276, or Vscp can be conjugatedto an anti-tumor agent.

In an example, a therapeutic agent is an anti-tumor agent such as acytotoxin, chemotherapeutic reagent, radionucleotide or a combinationthereof. Non-limiting examples of suitable chemotherapeutic agents forcoupling to antibodies to achieve an anti-tumor effect includefluorouracil, doxorubicin, adriamycin, daunorubicin, methotrexate,daunomycin, neocarzinostatin, and carboplatin. For example, theanti-tumor agent 5-fluorouracil can be conjugated to a specific bindingagent to treat a tumor such as breast cancer. Non-limiting examples ofsuitable toxins include bacterial, plant, and other toxins such asdiphtheria toxin, pseudomonas exotoxin A, staphylococcal enterotoxin A,abrin-A toxin, ricin A (deglycosylated ricin A and native ricin A),TGF-alpha toxin, cytotoxin from Chinese cobra (naja naja atra), andgelonin (a plant toxin). For example, the anti-tumor agent diphtheriatoxin can be conjugated to a specific binding agent such as CD276 totreat a tumor such as cancer.

Additional therapeutic agents can be used for coupling to specificbinding agents (such as antibodies) to generate an anti-tumor agent. Inan example, a therapeutic agent is a ribosome inactivating protein fromplants, bacteria and fungi. Non-limiting examples of suitable ribosomeinactivating proteins for coupling to specific binding agents (e.g.,antibodies) include restrictocin (a ribosome inactivating proteinproduced by Aspergillus restrictus), saporin (a ribosome inactivatingprotein from Saponaria officinalis), and RNase.

In a particular example, a therapeutic composition that includes atherapeutically effective amount of a binding agent specific for one ormore of the disclosed organ-specific or pathological angiogenesis markerproteins (as listed in Tables 8 and 9) further includes therapeuticallyeffective amounts of one or more other biologically active compounds.Examples of biologically active compounds include, but are not limitedto: anti-neoplastic agents (such as chemotherapeutics), antibiotics,alkylating agents, antioxidants, adjuvants, and so forth (such as thoselisted below under “additional treatments”). However, one skilled in theart will appreciate that the composition including a therapeuticallyeffective amount of a binding agent specific for one or more of thedisclosed pathological angiogenesis or organ-specific marker proteinsand the other biologically active compounds can also be administeredseparately (instead of in a single composition).

Depending on the endothelial marker, ligands or antibodies that targetthem may be directly shuttled across the endothelial layer into theunderlying tissue by a process known as transcytosis. [For example, seeMcIntosh et al. Proc. Natl. Acad. Sci. U.S.A. 2002 99(4):1996; Gumbletonet al. J. Control Release. 2003 87(1-3):139-51]. Thus, site-directedpharmacodelivery may be accomplished by use of cell surface endothelialmarkers specific for certain organs, such as liver or brain endothelium.Drugs can be conjugated to antibodies for selective delivery. A higherlocal concentration of drug may result in higher efficacy with fewerside effects. Even if antibodies directed to a particular endothelialmarker do not naturally enter a transcytotic pathway, they can be forcedto do so, for example through the generation of a bispecific antibodythat targets both the endothelial marker and a protein present incaveolae, such as Caveolin-1.

Pre-Screening Subjects

In some examples, subjects are initially screened to determine if theyhave increased expression levels of the disclosed pathologicalangiogenesis markers in their serum, whether they have a tumor that hasincreased expression levels of the disclosed pathological angiogenesismarkers or a combination thereof. For example, the pathologicalangiogenesis markers provided herein can be used to screen subjects todetermine if they are candidates for the disclosed therapies (seeSection III.B).

Exemplary Tumors

A tumor is an abnormal growth of tissue that results from excessive celldivision. A particular example of a tumor is cancer. For example, thecurrent application provides methods for the treatment (such as theprevention or reduction of metastasis) of tumors (such as cancers). Insome examples, the tumor is treated in vivo, for example in a mammaliansubject, such as a human subject. Exemplary tumors that can be treatedusing the disclosed methods include, but are not limited to: cancers ofthe liver, breast, colon, and lung, including metastases of such tumorsto other organs.

Treating Particular Organs

In further examples, methods of delivering a therapeutic or diagnosticagent to a specific organ to treat a disease are disclosed. In specificexamples, the method includes administering a therapeutically effectiveamount of a composition that includes a binding agent thatpreferentially binds to one or more organ-specific endothelial markerproteins provided in Table 8 and a therapeutic agent to evoke atherapeutic response in the specific organ.

In one example, a therapeutic agent is delivered to the brain via acomposition including a specific binding agent (such as an antibody) toone or more of the disclosed brain endothelial marker proteins in Table8 and a therapeutic agent to evoke a desired therapeutic response. Forexample, the one or more brain endothelial marker proteins is Glucosetransporter GLUT-1, Organic anion transporter 2, Pleiotrophin, ATPaseclass V, type 10A, Peptidoglycan recognition protein 1, Organic aniontransporter 14, Forkhead box Q1, Organic anion transporter 3, SN2(Solute carrier family 38, member 5), Inter-alpha (globulin) inhibitorH5, Solute carrier 38 member 3, Zinc finger protein of the cerebellum 2,Testican-2,3-HMG-CoA synthase 2, Progestin and adipoQ receptor familymember V, APC down-regulated 1 Drapc1, GDPD phosphodiesterase familyAccession No. NM_(—)001042671, putative transmembrane protein AccessionNo. NM_(—)029001, DES2 lipid desaturase/C4-hyroxylase, Kelch repeat andBTB (POZ) domain, Lipolysis stimulated receptor, GlutathioneS-transferase alpha 4, TNF receptor superfamily member 19, T-box 1 orputative secreted protein Accession No. XM_(—)620023). In anotherexample, the one or more brain endothelial marker proteins include GDPDphosphodiesterase family Accession No. NM_(—)001042671, Forkhead box Q1(FOXQ1), putative transmembrane protein Accession No. NM_(—)029001,Kelch repeat and BTB (POZ) domain, Progestin and adipoQ receptor familymember V, or putative secreted protein Accession No. XM_(—)620023 orcombinations thereof such as at least 1, at least 2, at least 3, or atleast 5 (for example, 1, 2, 3, 4, 5, or 6).

In a particular example, the desired therapeutic response is to reducethe growth of brain tumor cells or even kill the brain tumor cells (forexample the therapeutic agent inducing cells to undergo apoptosis). Suchreduced growth can in some examples decrease or slow metastasis of thebrain tumor, or reduce the size or volume of the brain tumor. In anotherexample, the desired therapeutic response is to treat a disease of thebrain such as depression or a stroke.

In additional examples, a therapeutic agent is delivered to the livervia a composition including a specific binding agent to the one or moreliver endothelial marker proteins and a therapeutic agent to evoke adesired therapeutic response. In an example, the specific binding agentis an antibody that specifically binds to one or more of the liverendothelial marker proteins disclosed in Table 8. In a further example,the one or more liver endothelial marker proteins is deoxyribonuclease1-like 3, LZP oncoprotein induced transcript 3, putative transmembraneprotein Accession No. NM_(—)023438, CD32 15, putative G-protein coupledreceptor NM_(—)033616, C-type lectin-like receptor 2, C-type lectindomain family 4 member g 16, Plexin C1, Wnt9B, Accession No. AK144596,GATA-binding protein 4, MBL-associated serine protease-3, Renin bindingprotein, putative transmembrane protein Accession No. NM_(—)144830, orRetinoic acid receptor, beta. In another example, the one or more liverendothelial marker proteins includes oncoprotein induced transcript 3,putative transmembrane protein Accession No. NM_(—)023438, putativeG-protein coupled receptor NM_(—)033616, Plexin C1, MBL-associatedserine protease-3, Accession No. AK144596, putative transmembraneprotein Accession No. NM_(—)144830 or combinations thereof such as atleast 1, at least 2, at least 3, or at least 5 (for example, 1, 2, 3, 4,5, 6, or 7).

In an example, the desired therapeutic response is to reduce the growthof liver tumor cells or even kill the liver tumor cells (for example thetherapeutic agent inducing cells to undergo apoptosis). Such reducedgrowth can in some examples decrease or slow metastasis of the livertumor, or reduce the size or volume of a liver tumor. In anotherexample, the desired therapeutic response is to treat a liver disease.

In further examples, a diagnostic agent is delivered to a specific organsuch as the brain or liver via a composition including a specificbinding agent such as an antibody to one or more of the disclosedorgan-specific endothelial marker proteins in Table 8. For example, adiagnostic agent can be delivered to the brain via a specific bindingagent that is capable of binding to one or more of the disclosed brainendothelial marker proteins to identify brain endothelial cells or toidentify a tumor. For instance, the vessels in tumors are often tortuousand dilated compared to normal vessels. In an example, organ-specificvessel markers can be used to detect tumors in a particular organ suchas the liver or brain.

Administration

Methods of administration of the disclosed compositions are routine, andcan be determined by a skilled clinician. For example, the disclosedtherapies (such as those that include a binding agent specific for oneor more of the disclosed pathological angiogenesis marker proteinslisted in Table 9 or the organ-specific markers listed in Table 8) canbe administered via injection, intratumorally, orally, topically,transdermally, parenterally, or via inhalation or spray. In a particularexample, a composition is administered intravenously to a mammaliansubject, such as a human.

The therapeutically effective amount of the agents administered can varydepending upon the desired effects and the subject to be treated. In oneexample, the method includes daily administration of at least 1 μg ofthe composition to the subject (such as a human subject). For example, ahuman can be administered at least 1 μg or at least 1 mg of thecomposition daily, such as 10 μg to 100 μg daily, 100 μg to 1000 μgdaily, for example 10 μg daily, 100 μg daily, or 1000 μg daily. In oneexample, the subject is administered at least 1 μg (such as 1-100 μg)intravenously of the composition including a binding agent thatspecifically binds to one or more of the disclosed organ-specific orpathological angiogenesis marker proteins. In one example, the subjectis administered at least 1 mg intramuscularly (for example in anextremity) of such composition. The dosage can be administered individed doses (such as 2, 3, or 4 divided doses per day), or in a singledosage daily.

In particular examples, the subject is administered the therapeuticcomposition that includes a binding agent specific for one or more ofthe disclosed organ-specific or pathological angiogenesis markerproteins on a multiple daily dosing schedule, such as at least twoconsecutive days, 10 consecutive days, and so forth, for example for aperiod of weeks, months, or years. In one example, the subject isadministered the therapeutic composition that a binding agent specificfor one or more of the disclosed organ-specific or pathologicalangiogenesis marker proteins daily for a period of at least 30 days,such as at least 2 months, at least 4 months, at least 6 months, atleast 12 months, at least 24 months, or at least 36 months.

The therapeutic compositions, such as those that include a binding agentspecific for one or more of the disclosed pathological angiogenesis ororgan-specific marker proteins, can further include one or morebiologically active or inactive compounds (or both), such asanti-neoplastic agents and conventional non-toxic pharmaceuticallyacceptable carriers, respectively.

In a particular example, a therapeutic composition that includes atherapeutically effective amount of a binding agent specific for one ormore of the disclosed pathological angiogenesis or organ-specific markerproteins further includes one or more biologically inactive compounds.Examples of such biologically inactive compounds include, but are notlimited to: carriers, thickeners, diluents, buffers, preservatives, andcarriers. The pharmaceutically acceptable carriers useful for theseformulations are conventional (see Remington's Pharmaceutical Sciences,by E. W. Martin, Mack Publishing Co., Easton, Pa., 19th Edition (1995)).In general, the nature of the carrier will depend on the particular modeof administration being employed. For instance, parenteral formulationscan include injectable fluids that include pharmaceutically andphysiologically acceptable fluids such as water, physiological saline,balanced salt solutions, aqueous dextrose, glycerol or the like as avehicle. For solid compositions (for example, powder, pill, tablet, orcapsule forms), conventional non-toxic solid carriers can include, forexample, pharmaceutical grades of mannitol, lactose, starch, ormagnesium stearate. In addition to biologically-neutral carriers,pharmaceutical compositions to be administered can include minor amountsof non-toxic auxiliary substances, such as wetting or emulsifyingagents, preservatives, and pH buffering agents and the like, for examplesodium acetate or sorbitan monolaurate.

Additional Treatments

In particular examples, prior to, during, or following administration ofa therapeutic amount of an agent that reduces or inhibits pathologicalangiogenesis due to the interaction of a binding agent with one or moreof the disclosed pathological angiogenesis marker proteins, the subjectcan receive one or more other therapies. In one example, the subjectreceives one or more treatments to remove or reduce the tumor prior toadministration of a therapeutic amount of a composition including abinding agent specific for one or more of the disclosed pathologicalangiogenesis marker proteins.

Examples of such therapies include, but are not limited to, surgicaltreatment for removal or reduction of the tumor (such as surgicalresection, cryotherapy, or chemoembolization), as well as anti-tumorpharmaceutical treatments which can include radiotherapeutic agents,anti-neoplastic chemotherapeutic agents, antibiotics, alkylating agentsand antioxidants, kinase inhibitors, and other agents. Particularexamples of additional therapeutic agents can that can be used includemicrotubule binding agents, DNA intercalators or cross-linkers, DNAsynthesis inhibitors, DNA and/or RNA transcription inhibitors,antibodies, enzymes, enzyme inhibitors, and gene regulators. Theseagents (which are administered at a therapeutically effective amount)and treatments can be used alone or in combination. Methods andtherapeutic dosages of such agents are known to those skilled in theart, and can be determined by a skilled clinician.

“Microtubule binding agent” refers to an agent that interacts withtubulin to stabilize or destabilize microtubule formation therebyinhibiting cell division. Examples of microtubule binding agents thatcan be used in conjunction with the disclosed therapy include, withoutlimitation, paclitaxel, docetaxel, vinblastine, vindesine, vinorelbine(navelbine), the epothilones, colchicine, dolastatin 15, nocodazole,podophyllotoxin and rhizoxin. Analogs and derivatives of such compoundsalso can be used and are known to those of ordinary skill in the art.For example, suitable epothilones and epothilone analogs are describedin International Publication No. WO 2004/018478. Taxoids, such aspaclitaxel and docetaxel, as well as the analogs of paclitaxel taught byU.S. Pat. Nos. 6,610,860; 5,530,020; and 5,912,264 can be used.

Suitable DNA and/or RNA transcription regulators, including, withoutlimitation, actinomycin D, daunorubicin, doxorubicin and derivatives andanalogs thereof also are suitable for use in combination with thedisclosed therapies.

DNA intercalators and cross-linking agents that can be administered to asubject include, without limitation, cisplatin, carboplatin,oxaliplatin, mitomycins, such as mitomycin C, bleomycin, chlorambucil,cyclophosphamide and derivatives and analogs thereof.

DNA synthesis inhibitors suitable for use as therapeutic agents include,without limitation, methotrexate, 5-fluoro-5′-deoxyuridine,5-fluorouracil and analogs thereof.

Examples of suitable enzyme inhibitors include, without limitation,camptothecin, etoposide, formestane, trichostatin and derivatives andanalogs thereof.

Suitable compounds that affect gene regulation include agents thatresult in increased or decreased expression of one or more genes, suchas raloxifene, 5-azacytidine, 5-aza-2′-deoxycytidine, tamoxifen,4-hydroxytamoxifen, mifepristone and derivatives and analogs thereof.

Kinase inhibitors include Gleevac, Iressa, and Tarceva that preventphosphorylation and activation of growth factors.

Other therapeutic agents, for example anti-tumor agents, that may or maynot fall under one or more of the classifications above, also aresuitable for administration in combination with the disclosed therapies.By way of example, such agents include adriamycin, apigenin, rapamycin,zebularine, cimetidine, and derivatives and analogs thereof.

In one example, the therapeutic composition (such as one including abinding agent specific for one or more of the disclosed pathologicalangiogenesis marker proteins) is injected into the subject in thepresence of an adjuvant. An adjuvant is an agent that when used incombination with an immunogenic agent augments or otherwise alters ormodifies a resultant immune response. In some examples, an adjuvantincreases the titer of antibodies induced in a subject by theimmunogenic agent. In one example, the one or more peptides areadministered to the subject as an emulsion with IFA and sterile waterfor injection (for example an intravenous or intramuscular injection).Incomplete Freund's Adjuvant (Seppic, Inc.) can be used as the Freund'sIncomplete Adjuvant (IFA) (Fairfield, N.J.). In some examples, IFA isprovided in 3 ml of a mineral oil solution based on mannide oleate(Montanide ISA-51). At the time of injection, the peptide(s) is mixedwith the Montanide ISA.51 and then administered to the subject. Otheradjuvants can be used, for example, Freund's complete adjuvant, B30-MDP,LA-15-PH, montanide, saponin, aluminum hydroxide, alum, lipids, keyholelympet protein, hemocyanin, a mycobacterial antigen, and combinationsthereof.

In some examples, the subject receiving the therapeutic peptidecomposition (such as one including a binding agent specific for one ormore of the disclosed pathological angiogenesis marker proteins) is alsoadministered interleukin-2 (IL-2), for example via intravenousadministration. In particular examples, IL-2 (Chiron Corp., Emeryville,Calif.) is administered at a dose of at least 500,000 IU/kg as anintravenous bolus over a 15 minute period every eight hours beginning onthe day after administration of the peptides and continuing for up to 5days. Doses can be skipped depending on subject tolerance.

In some examples, the disclosed compositions can be co-administered witha fully human antibody to cytotoxic T-lymphocyte antigen-4(anti-CTLA-4). In some example subjects receive at least 1 mg/kganti-CTLA-4 (such as 3 mg/kg every 3 weeks or 3 mg/kg as the initialdose with subsequent doses reduced to 1 mg/kg every 3 weeks).

In one example, at least a portion of the tumor (such as a metastatictumor) is surgically removed (for example via cryotherapy), irradiated,chemically treated (for example via chemoembolization) or combinationsthereof, prior to administration of the disclosed therapies (such asadministration of a binding agent specific for one or more of thedisclosed pathological angiogenesis marker proteins). For example, asubject having a metastatic tumor can have all or part of the tumorsurgically excised prior to administration of the disclosed therapies(such as one including a binding agent specific for one or more of thedisclosed pathological angiogenesis marker proteins). In anotherparticular example, the subject has a metastatic tumor and isadministered radiation therapy, chemoembolization therapy, or both,prior to administration of the disclosed therapies (such as oneincluding a binding agent specific for one or more of the disclosedpathological angiogenesis marker proteins).

In another example, the disclosed pathological angiogenesis markerproteins can be used as “surrogate” markers of angiogenesis that canalso be used to detect the efficacy of other previously disclosedanti-angiogenic agents in clinical trials.

Screening Subjects for Pathological Angiogenesis

Subjects can be screened prior to initiating the disclosed therapies,for example to determine whether the subject has pathologicalangiogenesis, a tumor, or a combination thereof. For example, thepresence of one or more of the disclosed pathological angiogenesismarker proteins listed in Table 9 can indicate that the subject haspathological angiogenesis and the tumor associated with the angiogenesiscan be treated using the methods provided herein. In one example, thepathological angiogenesis marker proteins are detected in a serumsample, such as pathological angiogenesis markers known to be secreted(e.g., Apelin, sCD137 and plgf), or cell surface molecules that aresusceptible to enzymatic cleavage at the cell surface (e.g., CD276,MiRP2, Doppel, PTPRN, CD109 or ankylosis). In another example, theproteins are detected in a tumor biopsy. Thus, the presence of therespective pathological angiogenesis marker proteins can be used todiagnose, or determine the prognosis of, a tumor in a subject.

In one example, pathological angiogenesis can be screened for bydetecting at least one expression product including one or more of:Vscp, CD276, ETSvg4 (Pea3), CD137(4-1BB), MiRP2, Ubiquitin D (Fat10),Doppel (prion-PLP), Apelin, Plgf, Ptprn (IA-2), CD109, Ankylosis, andcollagen VIII, 1, in a sample obtained from the subject. In someexamples, detection of the at least one expression product indicatespathological angiogenesis in the subject. In a further example,detection of the at least one expression product indicates the presenceof a tumor, such as cancer. For example, the biological sample can beincubated with an antibody that specifically binds to one or more of thedisclosed pathological angiogenesis marker proteins. The primaryantibody can include a detectable label. For example, the primaryantibody can be directly labeled, or the sample can be subsequentlyincubated with a secondary antibody that is labeled (for example with afluorescent label). The label can then be detected, for example bymicroscopy, ELISA, flow cytometery, or spectrophotometry. In anotherexample, the biological sample is analyzed by Western blotting for thepresence of at least one of the disclosed pathological angiogenesismarker proteins (see Table 9). In some examples, the level of expressionof at least one of the disclosed angiogenesis marker proteins can becompared to the level of expression of such proteins in a control (e.g.,non-cancer sample) or reference value.

In one example, the antibody that specifically binds an endothelialmarker (such as those listed in Table 9) is directly labeled with adetectable label. In another example, each antibody that specificallybinds an endothelial marker (the first antibody) is unlabeled and asecond antibody or other molecule that can bind the human antibody thatspecifically binds the respective endothelial marker is labeled. As iswell known to one of skill in the art, a second antibody is chosen thatis able to specifically bind the specific species and class of the firstantibody. For example, if the first antibody is a human IgG, then thesecondary antibody can be an anti-human-IgG. Other molecules that canbind to antibodies include, without limitation, Protein A and Protein G,both of which are available commercially.

Suitable labels for the antibody or secondary antibody include variousenzymes, prosthetic groups, fluorescent materials, luminescentmaterials, magnetic agents and radioactive materials. Non-limitingexamples of suitable enzymes include horseradish peroxidase, alkalinephosphatase, beta-galactosidase, or acetylcholinesterase. Non-limitingexamples of suitable prosthetic group complexes includestreptavidin/biotin and avidin/biotin. Non-limiting examples of suitablefluorescent materials include umbelliferone, fluorescein, fluoresceinisothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansylchloride or phycoerythrin. A non-limiting exemplary luminescent materialis luminol; a non-limiting exemplary magnetic agent is gadolinium, andnon-limiting exemplary radioactive labels include ¹²⁵I, ¹³¹I, ³⁵S or ³H.

In an alternative example, endothelial markers can be assayed in abiological sample by a competition immunoassay utilizing endothelialmarker standards labeled with a detectable substance and an unlabeledantibody that specifically binds the desired endothelial marker. In thisassay, the biological sample (such as serum), the labeled endothelialmarker standards and the antibody that specifically binds the desiredendothelial marker are combined and the amount of labeled endothelialmarker standard bound to the unlabeled antibody is determined. Theamount of endothelial marker in the biological sample is inverselyproportional to the amount of labeled endothelial marker standard boundto the antibody that specifically binds the endothelial marker.

In one example, a subject is screened by determining whether that haveincreased levels of one or more of the disclosed pathologicalangiogenesis marker proteins in their serum (for example relative to alevel present in a serum sample from a subject not having a tumor), forexample using an antibody that specifically binds one or more of thedisclosed pathological angiogenesis markers (such as those describedbelow).

As an alternative to analyzing the sample for the presence of proteins,the presence of nucleic acids can be determined. For example, thebiological sample can be incubated with primers that permit theamplification of one or more of the pathological angiogenesis markermRNAs, under conditions sufficient to permit amplification of suchproducts (see, for example, primer sequences provided in Example 1).Exemplary methods include SAGE and PCR. In another example, thebiological sample is incubated with probes that can bind to one or moreof the disclosed pathological angiogenesis marker nucleic acid sequences(such as cDNA, genomic DNA, or RNA (such as mRNA)) under high stringencyconditions. The resulting hybridization products can then be detectedusing methods known in the art. In one example, a subject is screened bydetermining whether that have increased levels of one or more thedisclosed pathological angiogenesis marker nucleic acids in their serum(for example relative to a level present in adjacent non-tumor cellsfrom the same subject), for example detecting mRNA expression of one ormore the disclosed pathological angiogenesis markers.

Generation of Antibodies

One of ordinary skill in the art can readily generate antibodies whichspecifically bind to the disclosed endothelial marker proteins. Theseantibodies can be monoclonal or polyclonal. They can be chimeric orhumanized. Any functional fragment or derivative of an antibody can beused including Fab, Fab′, Fab2, Fab′2, and single chain variableregions. So long as the fragment or derivative retains specificity ofbinding for the endothelial marker protein it can be used in the methodsprovided herein. Antibodies can be tested for specificity of binding bycomparing binding to appropriate antigen to binding to irrelevantantigen or antigen mixture under a given set of conditions. If theantibody binds to appropriate antigen at least 2, at least 5, at least 7or 10 times more than to irrelevant antigen or antigen mixture, then itis considered to be specific.

In an example, monoclonal antibodies are generated to the endothelialcell markers disclosed in Tables 8 and 9. These monoclonal antibodieseach include a variable heavy (V_(H)) and a variable light (V_(L)) chainand specifically bind to the specific endothelial cell markers. Forexample, the antibody can bind the specific endothelial cell markerswith an affinity constant of at least 10⁶ M⁻¹, such as at least 10⁷ M⁻¹,at least 10⁸ M⁻¹, at least 5×10⁸ M⁻¹, or at least 10⁹ M⁻¹.

The specific antibodies can include a V_(L) polypeptide having aminoacid sequences of the complementarity determining regions (CDRs) thatare at least about 90% identical, such as at least about 95%, at leastabout 98%, or at least about 99% identical to the amino acid sequencesof the specific endothelial marker proteins and a V_(H) polypeptidehaving amino acid sequences of the CDRs that are at least about 90%identical, such as at least about 95%, at least about 98%, or at leastabout 99% identical to the amino acid sequences of the specificendothelial marker proteins.

In one example, the sequence of the specificity determining regions ofeach CDR is determined. Residues that are outside the SDR (non-ligandcontacting sites) are substituted. For example, in any of the CDRsequences, at most one, two or three amino acids can be substituted. Theproduction of chimeric antibodies, which include a framework region fromone antibody and the CDRs from a different antibody, is well known inthe art. For example, humanized antibodies can be routinely produced.The antibody or antibody fragment can be a humanized immunoglobulinhaving CDRs from a donor monoclonal antibody that binds one of thedisclosed endothelial marker proteins and immunoglobulin and heavy andlight chain variable region frameworks from human acceptorimmunoglobulin heavy and light chain frameworks. Generally, thehumanized immunoglobulin specifically binds to one of the disclosedendothelial marker proteins with an affinity constant of at least 10⁷M⁻¹, such as at least 10⁸ M⁻¹ at least 5×10⁸ M⁻¹ or at least 10⁹ M⁻¹.

In another example, human monoclonal antibodies to the disclosedspecific endothelial marker proteins in Tables 8 and 9 are produced.Human monoclonal antibodies can be produced by transferring donorcomplementarity determining regions (CDRs) from heavy and light variablechains of the donor mouse immunoglobulin into a human variable domain,and then substituting human residues in the framework regions whenrequired to retain affinity. The use of antibody components derived fromhumanized monoclonal antibodies obviates potential problems associatedwith the immunogenicity of the constant regions of the donor antibody.For example, when mouse monoclonal antibodies are used therapeutically,the development of human anti-mouse antibodies (HAMA) leads to clearanceof the murine monoclonal antibodies and other possible adverse events.Chimeric monoclonal antibodies, with human constant regions, humanizedmonoclonal antibodies, retaining only murine CDRs, and “fully human”monoclonal antibodies made from phage libraries or transgenic mice haveall been used to reduce or eliminate the murine content of therapeuticmonoclonal antibodies.

Techniques for producing humanized monoclonal antibodies are described,for example, by Jones et al., Nature 321:522, 1986; Riechmann et al.,Nature 332:323, 1988; Verhoeyen et al., Science 239:1534, 1988; Carteret al., Proc. Natl. Acad. Sci. U.S.A. 89:4285, 1992; Sandhu, Crit. Rev.Biotech. 12:437, 1992; and Singer et al., J. Immunol. 150:2844, 1993.The antibody may be of any isotype, but in several embodiments theantibody is an IgG, including but not limited to, IgG₁, IgG₂, IgG₃ andIgG₄.

In one example, the sequence of the humanized immunoglobulin heavy chainvariable region framework can be at least about 65% identical to thesequence of the donor immunoglobulin heavy chain variable regionframework. Thus, the sequence of the humanized immunoglobulin heavychain variable region framework can be at least about 75%, at leastabout 85%, at least about 99% or at least about 95%, identical to thesequence of the donor immunoglobulin heavy chain variable regionframework. Human framework regions, and mutations that can be made in ahumanized antibody framework regions, are known in the art (see, forexample, in U.S. Pat. No. 5,585,089).

Antibodies, such as murine monoclonal antibodies, chimeric antibodies,and humanized antibodies, include full length molecules as well asfragments thereof, such as Fab, F(ab′)₂, and Fv, which include a heavychain and light chain variable region and are capable of binding theepitopic determinant. These antibody fragments retain some ability toselectively bind with their antigen or receptor. These fragmentsinclude: (1) Fab, the fragment which contains a monovalentantigen-binding fragment of an antibody molecule, can be produced bydigestion of whole antibody with the enzyme papain to yield an intactlight chain and a portion of one heavy chain; (2) Fab′, the fragment ofan antibody molecule can be obtained by treating whole antibody withpepsin, followed by reduction, to yield an intact light chain and aportion of the heavy chain; two Fab′ fragments are obtained per antibodymolecule; (3) (Fab′)₂, the fragment of the antibody that can be obtainedby treating whole antibody with the enzyme pepsin without subsequentreduction; F(ab′)₂ is a dimer of two Fab′ fragments held together by twodisulfide bonds; (4) Fv, a genetically engineered fragment containingthe variable region of the light chain and the variable region of theheavy chain expressed as two chains; and (5) Single chain antibody (suchas scFv), defined as a genetically engineered molecule containing thevariable region of the light chain, the variable region of the heavychain, linked by a suitable polypeptide linker as a genetically fusedsingle chain molecule. Methods of making these fragments are known inthe art (see for example, Harlow and Lane, Antibodies: A LaboratoryManual, Cold Spring Harbor Laboratory, New York, 1988). Fv antibodiesare typically about 25 kDa and contain a complete antigen-binding sitewith three CDRs per each heavy chain and each light chain. To producethese antibodies, the V_(H) and the V_(L) can be expressed from twoindividual nucleic acid constructs in a host cell. If the V_(H) and theV_(L) are expressed non-contiguously, the chains of the Fv antibody aretypically held together by noncovalent interactions. However, thesechains tend to dissociate upon dilution, so methods have been developedto crosslink the chains through glutaraldehyde, intermoleculardisulfides, or a peptide linker. Thus, in one example, the Fv can be adisulfide stabilized Fv (dsFv), wherein the heavy chain variable regionand the light chain variable region are chemically linked by disulfidebonds.

In an additional example, the Fv fragments include V_(H) and V_(L)chains connected by a peptide linker. These single-chain antigen bindingproteins (scFv) are prepared by constructing a structural genecomprising DNA sequences encoding the V_(H) and V_(L) domains connectedby an oligonucleotide. The structural gene is inserted into anexpression vector, which is subsequently introduced into a host cellsuch as E. coli. The recombinant host cells synthesize a singlepolypeptide chain with a linker peptide bridging the two V domains.Methods for producing scFvs are known in the art (see Whitlow et al.,Methods: a Companion to Methods in Enzymology, Vol. 2, page 97, 1991;Bird et al., Science 242:423, 1988; U.S. Pat. No. 4,946,778; Pack etal., Bio/Technology 11:1271, 1993; and Sandhu, supra).

Antibody fragments can be prepared by proteolytic hydrolysis of theantibody or by expression in E. coli of DNA encoding the fragment.Antibody fragments can be obtained by pepsin or papain digestion ofwhole antibodies by conventional methods. For example, antibodyfragments can be produced by enzymatic cleavage of antibodies withpepsin to provide a 5S fragment denoted F(ab′)₂. This fragment can befurther cleaved using a thiol reducing agent, and optionally a blockinggroup for the sulfhydryl groups resulting from cleavage of disulfidelinkages, to produce 3.5S Fab′ monovalent fragments. Alternatively, anenzymatic cleavage using pepsin produces two monovalent Fab′ fragmentsand an Fc fragment directly (see U.S. Pat. No. 4,036,945 and U.S. Pat.No. 4,331,647, and references contained therein; Nisonhoff et al., Arch.Biochem. Biophys. 89:230, 1960; Porter, Biochem. J. 73:119, 1959;Edelman et al., Methods in Enzymology, Vol. 1, page 422, Academic Press,1967; and Coligan et al. at sections 2.8.1-2.8.10 and 2.10.1-2.10.4).

Other methods of cleaving antibodies, such as separation of heavy chainsto form monovalent light-heavy chain fragments, further cleavage offragments, or other enzymatic, chemical, or genetic techniques may alsobe used, so long as the fragments bind to the antigen that is recognizedby the intact antibody.

One of skill will realize that conservative variants of the antibodiescan be produced. Such conservative variants employed in antibodyfragments, such as dsFv fragments or in scFv fragments, will retaincritical amino acid residues necessary for correct folding andstabilizing between the V_(H) and the V_(L) regions, and will retain thecharge characteristics of the residues in order to preserve the low pIand low toxicity of the molecules. Amino acid substitutions (such as atmost one, at most two, at most three, at most four, or at most fiveamino acid substitutions) can be made in the V_(H) and the V_(L) regionsto increase yield. Conservative amino acid substitution tables providingfunctionally similar amino acids are well known to one of ordinary skillin the art. The following six groups are examples of amino acids thatare considered to be conservative substitutions for one another: 1)Alanine (A), Serine (S), Threonine (T); 2) Aspartic acid (D), Glutamicacid (E); 3) Asparagine (N), Glutamine (Q); 4) Arginine (R), Lysine (K);5) Isoleucine (I), Leucine (L), Methionine (M), Valine (V); and 6)Phenylalanine (F), Tyrosine (Y), Tryptophan (W).

Antibodies are commercially available for many of the endothelialmarkers disclosed herein (see Tables 1-4).

TABLE 1 Antibodies for Brain Endothelial Markers (BEMs) Gene AccessionNo. Gene Commercial Source NM_011400 Glucose transporter GLUT-1 abcam ®NM_030687 Organic anion transporter 2 Alpha Diagnostic InternationalNM_008973 Pleiotrophin abcam ® NM_009728 ATPase, class V, type 10AOrbigen NM_009402 Peptidoglycan recognition protein 1 IMGENEX NM_008239Forkhead box Q1 abcam ® NM_031194 Organic anion transporter 3 AlphaDiagnostic International NM_172479 SN2, Solute carrier family 38, member5 abcam ® NM_010703 Lymphoid enhancer binding factor 1 Aviva SystemsBiology NM_011404 Solute carrier family 7, member 5 BIODESIGNInternational NM_023805 Solute carrier family 38, member 3 BDBiosciences Pharmingen NM_009574 Zinc finger protein of the cerebellum 2BIODESIGN International NM_052994 Testican-2 R & D Systems NM_028748Progestin and adipoQ receptor family Abnova Corporation member VNM_010357 Glutathione S-transferase, alpha 4 Lab Vision NM_011532 T-box1 BioCarta

TABLE 2 Antibodies for Liver Endothelial Markers (LEMs) Gene AccessionNo. Gene Commercial Source NM_007870 Deoxyribonuclease 1-like 3 Abnova ®Corporation AK150613 CD32 15 Eurogenetics NM_019985 C-type lectin-likereceptor 2 R & D Systems NM_018797 Plexin C1 Novus Biologicals NM_008092GATA-binding protein 4 CeMines AB049755 MBL-associated serine HyCultbiotechnology b.v. protease-3 NM_023132 Renin binding protein NovusBiologicals NM_011243 Retinoic acid receptor, beta abcam ®

TABLE 3 Antibodies for Physiological Angiogenesis Endothelial MarkersGene Accession No. Gene Commercial Source NM_026785 Ube2c Novusbiologicals NM_011623 DNA topo II Leinco Technologies, Inc. NM_008381Inhibin beta-B AbDSerotec NM_025415 Cks2 Novus biologicals NM_009387 TK1Novus biologicals NM_011607 Tenascin C abcam ® NM_024435 NeurotensinCalbiochem NM_145150 Prc1 Biolegend XM_133912 Ki67 antigen abcam ®NM_016780 beta-Integrin ABR—Affinity BioReagents

TABLE 4 Antibodies for Pathological Angiogenesis Endothelial MarkersGene Accession No. Gene Commercial Source DQ832276 CD276 (B7-H3)eBioscience, Inc. DQ832277 ETSvg4 (Pea3) Santa Cruz BiotechnologyDQ832278¦ CD137 (4-1BB) GeneTex DQ832280 MiRP2 almone labs NM_023137Ubiquitin D (FAT10) R & D Systems DQ832281 Doppel (Prion-PLP) abcam ®DQ832282 Apelin ABR—Affinity BioReagents NM_008827 Plgf R & D SystemsDQ832283 Ptprn (IA-2) abcam ® DQ832284 CD109 abcam ® NM_007739 Coll.VIII, α1 Cosmo Bio Corp., Ltd.

Conjugation of Therapeutic or Diagnostic Agents to Antibodies

Binding agents, such as antibodies of this disclosure, can be conjugatedor linked to an effector molecule, such as a therapeutic agent (such asan anti-tumor agent) or a diagnostic agent (such as a fluorescentmoiety), using any number of methods known to those of skill in the art(for example, see Harlow and Lane, Using Antibodies: A LaboratoryManual, CSHL, New York, 1999; Yang et al., Nature, 382:319-24, 1996).Both covalent and noncovalent attachment means can be used.

The procedure for attaching an effector molecule to an antibody variesaccording to the chemical structure of the effector. Polypeptidestypically contain a variety of functional groups; such as carboxylicacid (COOH), free amine (—NH₂) or sulfhydryl (—SH) groups, which areavailable for reaction with a suitable functional group on an antibodyto result in the binding of the effector molecule. Alternatively, theantibody is derivatized to expose or attach additional reactivefunctional groups. The derivatization can involve attachment of any of anumber of linker molecules such as those available from Pierce ChemicalCompany, Rockford, Ill. The linker can be any molecule used to join theantibody to the effector molecule (e.g., therapeutic agent or diagnosticagent). The linker is capable of forming covalent bonds to both theantibody and to the effector molecule. Suitable linkers are well knownto those of skill in the art and include, but are not limited to,straight or branched-chain carbon linkers, heterocyclic carbon linkers,or peptide linkers. Where the antibody and the effector molecule arepolypeptides, the linkers can be joined to the constituent amino acidsthrough their side groups (such as through a disulfide linkage tocysteine) or to the alpha carbon amino and carboxyl groups of theterminal amino acids.

In some circumstances, it is desirable to free the effector moleculefrom the antibody when the immunoconjugate has reached its target site.Therefore, in these circumstances, immunoconjugates can include linkagesthat are cleavable in the vicinity of the target site. Cleavage of thelinker to release the effector molecule from the antibody may beprompted by enzymatic activity or conditions to which theimmunoconjugate is subjected either inside the target cell or in thevicinity of the target site. When the target site is a tumor, a linkerwhich is cleavable under conditions present at the tumor site (forexample, when exposed to tumor-associated enzymes or acidic pH) can beused.

In view of the large number of methods that have been reported forattaching a variety of radiodiagnostic compounds, radiotherapeuticcompounds, label (such as enzymes or fluorescent molecules) drugs,toxins, and other agents to antibodies one skilled in the art will beable to determine a suitable method for attaching a given agent to anantibody or other polypeptide.

The subject matter of the present disclosure is further illustrated bythe following non-limiting Examples.

EXAMPLES Example 1 Materials and Methods

Cell lines and animal studies. EMT6 cells were a kind gift of Dr. RobertS. Kerbel, KM12SM cells were a kind gift of Isaiah J. Fidler, HCT116cells were from the DCT tumor repository (NCI, Frederick) and LS174T,SW620, CT26 and LLC were from the American Type Culture Collection(Manassas, Va.). Tumor cell lines were maintained in DMEM containing 10%fetal bovine serum. Tumors were made by inoculating 5×10⁵−1×10⁶ cellssubcutaneously or intrasplenically. To produce liver metastasis byintrasplenic injection, the spleen was exteriorized through a leftlateral incision prior to tumor cell injection. The tumor cellsuspension was allowed to enter the portal circulation over a period offive minutes, after which the spleen was removed and the skin sutured.For partial hepatectomy, the liver was exposed through a midlineabdominal incision and the two anterior lobes were exteriorized and thesuspensory ligaments severed. The left lateral and caudal lobes weregently tied off using 6-0 sterile silk prior to excision leaving a 3 mmstump above the silk. The procedure results in the removal of ˜70% ofliver volume. The remaining liver was placed back into the peritonealcavity and the peritoneal cavity and skin are sutured.

Endothelial cell isolations and construction of SAGE libraries.Immediately following CO₂ euthanasia, normal or tumor tissues wereresected, diced with a razor, and digested in Hepatocyte Wash Buffer(Invitrogen, Carlsbad, Calif.) containing 2 mg/ml collagenase A (Roche)for 1-hour at 37° C. All subsequent steps were performed on ice or at 4°C. After filtering sequentially through 100 and 25-μm mesh, cells werepelleted and rinsed repeatedly with PBS containing 0.5% BSA (PBS/BSA)until the supernatant was transparent. To remove hematopoietic cellsfrom the sample, cells were incubated with a mixture ofstreptavidin-linked dynabeads (Dynal, Lake Success, N.Y.) that had beenseparately pre-bound to biotin anti-CD19, biotin anti-CD45 (BDPharmingen, San Diego, Calif.) or biotin anti-F480 (Caltag Laboratories,Burlingame, Calif.) and then mixed at a 1:1:1 ratio. To preventnon-specific binding of Fc-receptor containing cells in the positiveselection, anti-CD16/32 antibodies (Fc Block; BD Pharmingen) were addedto the cell suspension. To label ECs from heart, kidney, intestine,liver, lung, KM12 tumors and LS174T tumors, biotinylated rat anti-mouseCD105 (eBioscience, San Diego, Calif.) was added; to label ECs fromspleen, CT26 tumors or LLC tumors biotinylated goat anti-mouseVE-cadherin (R&D Systems, Minneapolis, Minn.) was added, and to labelECs from brain, muscle, EMT6 tumors and SW620 a mixture of bothantibodies was added. After rinsing 5× with PBS/BSA, streptavidin-linkeddynabeads were added to the cell suspension, rotated 5 minutes at 4° C.,diluted to 40 ml with PBS/BSA and bead-bound cells were captured using aDynal MPC-50 magnet. Captured ECs were rinsed 5-10 times until onlybead-bound cells were observed. Cells were resuspended in mRNAlysis/binding buffer for SAGE or mRNA extraction buffer for RT-PCR.After removing the beads, lysates were stored at −80° C. until ready touse.

Construction of SAGE libraries. LongSAGE libraries were constructedusing the I-SAGE Long Kit (Invitrogen) and a previously establishedMicroSAGE protocol by St. Croix et al. (available from John HopkinsOncology Center, Baltimore, Md. 21231) which is herein incorporated byreference in its entirety. Ditags were PCR amplified using biotinylatedprimers to facilitate efficient linker removal and Mme-I enzyme waspurchased from New England Biolabs (Ipswich, Mass.). SAGE tags used toidentify various endothelial cell markers are included in Tables 5A-5D.Some genes have multiple tags due to alternative polyadenylation sites,internal polyA stretches, and antisense transcripts. The number of timeseach tag was observed was normalized to 100,000 tags and is indicated inparenthesis following the tag sequence in Tables 5A-5D. For genes withmultiple SAGE tags, counts for individual tags were summed to obtain thetotal number of tags. Each tag is preceded by the sequence CATG.Antisense tags are followed by an asterisk.

TABLE 5A SAGE tags used to identify Brain Endothelial Markers. SEQ IDNO: Acc# SAGE Tags  1 NM_011400 AGAAGGACCTCGGAGGC (512)  2 NM_011400TGCTTCCAGTATGTGGA (124)  3 NM_011400 GTGTTTGTGTGGCCCTC* (104)  4NM_011400 AGAAGGACTTCGGAGGC (8)  5 NM_011400 CCTGAATTGCTGAGGCC (5)  6NM_030687 AGGGACTTCAGTCCCTC (137)  7 NM_030687 ATAAAAAATATTTACTG (11)  8NM_030687 CCCCACCAAAAATCAAT (9)  9 NM_008973 AAATCCTTTCACTTTGG (72) 10NM_008973 TAAACTACTTCTCTTGT (15) 11 NM_008973 TTTCAATCTTATCTTAA (7) 12NM_009728 GGTCTGACAGCTCCGGT (32) 13 NM_009402 GACCGGGTACCCGCAAA (40) 14NM_021471 ACAAACCTCTAAGGATG (15) 15 NM_021471 CGCTGCAAGGGATCGTG (7) 16NM_021471 TAAATGAATAAAAGCAT (4) 17 NM_008239 GGGTAAATGATGACTAC (15) 18NM_008239 GGCAAGTTCCCCTTTTT (9) 19 NM_008239 GAGTGGTTCCCTGATGT* (5) 20NM_031194 CTCTCAGAACAAAGACT (14) 21 NM_031194 CCAACCTACTCTATTGC (5) 22NM_172479 AGAGGAGGTATGGGAGG 23 NM_172471 AGGAGAGTGTCTAAAAG (24) 24NM_172471 CACAAATATTTACCATT (13) 25 NM_172471 AGTTTCCACCTTTATTC (4) 26NM_010703 GTGGTAAGAGAAGCTCC (12) 27 NM_011404 TCACTGCCCTGAAAGAC (23) 28NM_023805 ACTTACATTCCACTGCT (20) 29 NM_009574 TGATGTTTCAGTGCTTT (8) 30NM_009574 AGTCCTCCCCTCAGGGC (6) 31 NM_009574 CTTCCTAGTCTTTTTGA (2) 32NM_052994 TTTTAGTAAGAAAGCAG (49) 33 NM_052994 CCTCAGCACGCCCTCAG (27) 34NM_052994 GGACCCCTGACTGTGAT (4) 35 NM_008256 CTGCTGTGGACCAGAGC (19) 36NM_008256 AATGTGTTCTATCCCTC (7) 37 NM_028748 ACTTCAGAATGTGCCAG (7) 38NM_028748 GTGGATGCCAATTTGCC (5) 39 NM_028748 ATACCAAACACGCCAAT (3) 40AK172004 GTGCATACTTGAGGGGG (68) 41 NM_001042671 ACTTTAATACCACTTAG* (6)42 NM_001042671 CAGAAAAATAAATGTCC (4) 43 NM_001042671 TATTGACAGAAGTTAAA(4) 44 NM_029001 CACAAGCTGTTAGAGGC (11) 45 NM_029001 CTTACAATGAGAAGCGA(6) 46 NM_029001 GGCGCCACACAACGTTG (4) 47 NM_029001 TCCTGCCATTCACAAAT(3) 48 NM_029001 TGATTGGCTTACCTCAG (2) 49 NM_027299 GAACACCACGACTTCCC(19) 50 XM_486083 CGGAAACTGCCAGTGCT (37) 51 XM_486083 CGGAAACTGCCAAAAAA(2) 52 NM_017405 GGAGCAGGAACCCCTTC (46) 53 NM_010357 TATGCAGATGGCACCCA(36) 54 NM_013869 GCTCTTAAGAGAGTTTG (9) 55 NM_011532 CGGGTTTCCCGCCCGCC(17) 56 XM_620023 CAACGCCAGCCTCTCCC (6)

TABLE 5B SAGE tags used to identify Liver Endothelial Markers. SEQ IDNO: Acc# SAGE Tags 57 NM_007870 TGTAACCTGAAGAAATA (122) 58 NM_007870CAGATAGCTTAGACCTA* (38) 59 NM_007870 GGTGATTTCAACGCCGG (16) 60 NM_007870GTGCTTGCTTGTGTGCA* (15) 61 NM_007870 CCAAATCTGTCCTGTTG* (6) 62 NM_010959CAGGCAAACCACTCATA (28) 63 NM_010959 ATCTCCTAGATACCTAA (26) 64 NM_010959AAAGGACTGGCTGGCTG (5) 65 NM_023438 GGGTGGGTGAAGGCAGA (16) 66 AK150613TTACTTTAATAGTAAAA (66) 67 AK150613 GTACAGTGTAGATAATT (32) 68 AK150613TATAGGCTTTCTAAAAA* (6) 69 AK150613 AGTTCAGAGTGTAGACA (5) 70 AK150613TGTGTGGGCTGCCTATG* (5) 71 AK150613 ATTACCAGAACCACATT (5) 72 AK150613CGAAGGGACCCACAACC (4) 73 NM_033616 GGTCTTACCTCACCACG (22) 74 NM_033616TTGCTTGGAACCGCATT* (5) 75 NM_019985 CAATAAAAGATCTGGAC (14) 76 NM_029465CTTTAGTGACCCCAGCT (219) 77 NM_029465 ATGGTGGGCACTGCTCA* (14) 78NM_029465 TCCTCTGGAATCATTGG (6) 79 NM_018797 AGTCCTGTGTGAGCCTT (23) 80NM_029465 ATGGTGGGCACTGCTCA* (14) 81 NM_029465 TCCTCTGGAATCATTGG (6) 82NM_011719 CTTCCTGTCTGAGCACT (9) 83 AK144596 GGGTTGTAAGGAATTTT (16) 84NM_008092 CCTGCCCCTCCTCCACA (7) 85 NM_008092 ATAGCAGCTGTCCTAGG (2) 86AB049755 TAAAGGATACTATATTT (6) 87 AB049755 AGTCCTGGGTTCTGTCC (4) 88NM_023132 AAGGCTCGAAATAAAGA (5) 89 NM_144830 GATGAATCTTTTTCAAG (14) 90NM_144830 GATTCTCTGCATCAGGC (7) 91 NM_144830 TTGGTTACCCAGCTCCG (5) 92NM_011243 GAGTCTCCTGGCAAAGA (10) 93 NM_011243 AATAACCAGGCCTCACG (1)

TABLE 5C SAGE tags used to identify Physiological AngiogenesisEndothelial Markers. Gene (SEQ ID NO) SAGE tags Ube2c ACATCTGGTGACAAAGG(47) (SEQ ID NO: 94) Ube2c GGTATCTGCTGGACAGG (5) (SEQ ID NO: 95)TRAF4af1 CTGTCCCCTTGTCTCTC (31) (SEQ ID NO: 96) TRAF4af1GAGCTGTCTTATGTGTC (2) (SEQ ID NO: 97) TRAF4af1 TTTCCGAGTCTCTAGAG* (1)(SEQ ID NO: 98) TRAF4af1 TTTCCGAGTCTCTAGAG* (1) (SEQ ID NO: 99) DNA topoII alpha AGAAGTTGCTCGTACCT (60) (SEQ ID NO: 100) DNA topo II alphaCCCCTGTGGTATCTGAC (7) (SEQ ID NO: 101) DNA topo II alphaGAGTTGTCACCGCTGCA (5) (SEQ ID NO: 102) DNA topo II alphaTTACAGAGAGCAAAGCT (4) (SEQ ID NO: 103) DNA topo II alphaTAGGTTGCTTAAAGAAA (3) (SEQ ID NO: 104) DNA topo II alphaACCAAAAAGCAAGTTGG (2) (SEQ ID NO: 105) DNA topo II alphaGGCAATTGTCTTCTCTG (1) (SEQ ID NO: 106) DNA topo II alphaGCTTAAACAAAATGCAT (1) (SEQ ID NO: 107) Ckap2 CCTAAGTATGGTACAGG (25) (SEQID NO: 108) Inhibin beta-B GTTAGTCAGAAACTGCC (98) (SEQ ID NO: 109)Inhibin beta-B TACAGTATAAGACAATA (22) (SEQ ID NO: 110) Inhibin beta-BAACGTAAAATACTTAAG (20) (SEQ ID NO: 111) Inhibin beta-B GGTCTTTGAGGGAGCAG(4) (SEQ ID NO: 112) Inhibin beta-B TCCCCTGCCCAGTTCAC (4) (SEQ ID NO:113) Inhibin beta-B CTTTGAGGCCAGCAGAG (1) (SEQ ID NO: 114) Cks2CGCTGTATTCTTCACAG (41) (SEQ ID NO: 115) Thymidine kinase 1GAGTGCTTCCGAGAAGC (66) (SEQ ID NO: 116) Tenascin C GTCATTCTCCGAGCCAG(76) (SEQ ID NO: 117) Tenascin C GTGTTGCTGTCACTAGG* (3) (SEQ ID NO: 118)Tenascin C AGTACTCAATCCAGTTT (1) (SEQ ID NO: 119) NeurotensinTAAATTGGATGCAATGT (22) (SEQ ID NO: 120) Neurotensin GATATTTTGCCTGTCAA(13) (SEQ ID NO: 121) Neurotensin ATGACGACCTTGTTGGC (2) (SEQ ID NO: 122)Prc1 GAGTCAGCAACTTTGCA (38) (SEQ ID NO: 123) Prc1 AAGTAATTCTGGTAACA (1)(SEQ ID NO: 124) Prc1 ATGCCGAGATTGTACGG (1) (SEQ ID NO: 125) Ki67antigen AGGAAGATCACCAGGGA (48) (SEQ ID NO: 126) Ki67 antigenCTAATGGCCCATTAGTG (4) (SEQ ID NO: 127) Ki67 antigen AAGGAAGAAAGCTCTGC(2) (SEQ ID NO: 128) Ki67 antigen CTTGAGGTCTAGAGGAA (2) (SEQ ID NO: 129)Ki67 antigen AGAGAATTTTCCATACT (1) (SEQ ID NO: 130) Ki67 antigenATTTCCATCTTCATACC* (1) (SEQ ID NO: 131) Integrin beta 3CTAGGCAAGAACATTAC (45) (SEQ ID NO: 132) Integrin beta 3ACCGGAAGGAATTTGCT (6) (SEQ ID NO: 133) Integrin beta 3 ATGCCCGGCAGGTGCTC(3) (SEQ ID NO: 134) Integrin beta 3 GACTACCCATCTCTGGG (3) (SEQ ID NO:135) Integrin beta 3 GTTTGCTCTGCTGGCAT (2) (SEQ ID NO: 136)

TABLE 5D SAGE tags used to identify Pathological AngiogenesisEndothelial Markers. Gene (SEQ ID NO.) SAGE tags Vscp GCTCTGTGTCTATGCAG(22) (SEQ ID NO: 137) Vscp GCTCTCTTGTGTGCACT (16), (SEQ ID NO: 138) VscpGCTGGCACTGGTAACCT (8) (SEQ ID NO: 139) Vscp GGGGAAGGCTGGTGGTC* (2) (SEQID NO: 140) Vscp CAGAGGGCTGGGGCCGG (1) (SEQ ID NO: 141) CD276AGACTGTAAACTGGGTG (17) (SEQ ID NO: 142) CD276 GGACTCTGTAAACTGGG (17)(SEQ ID NO: 143) CD276 GGACTCTGGCCAGCACC (1) (SEQ ID NO: 144) CD276GTGCTATTCTGGAGCTG (1) (SEQ ID NO: 145) Ets variant gene 4TGGGCGGCAGCTGGGGG (27) (SEQ ID NO: 146) Ets variant gene 4CAATGTGGGAAGTGGAG (4) (SEQ ID NO: 147) Ets variant gene 4GGGGGTTGGGAGAGGGG (2) (SEQ ID NO: 148) Ets variant gene 4TGGGAGGCAGCTGGGGG (2) (SEQ ID NO: 149) CD137 ACTCCTGGACAGCTCAA (29) (SEQID NO: 150) CD137 CATCATATTTGCACACA (4) (SEQ ID NO: 151) CD137GGAAACAACTGTTACAA (3) (SEQ ID NO: 152) CD137 GTGGACTGGAAGGCCGC (2) (SEQID NO: 153) CD137 GGTCTCCCCCTTCAGAC (1) (SEQ ID NO: 154) MiRP2AGAAACCTTGATAAAAC (84) (SEQ ID NO: 155) Ubiquitin D GCTGACTACAACATCAA(11) (SEQ ID NO: 156) Prion-PLP AAGTATTCCACAGTACA (16) (SEQ ID NO: 157)Prion-PLP AAGCAGGGCGGAACCTT (5) (SEQ ID NO: 158) Prion-PLPTGTGTTCTTAGGCATCT (2) (SEQ ID NO: 159) Prion-PLP GTCATCTAAAAGGACTA (2)(SEQ ID NO: 160) Prion-PLP TGATTTTGACTGCAAAT (1) (SEQ ID NO: 161) ApelinGTTCTATACTCTTCTGG (11) (SEQ ID NO: 162) Apelin TAAATATGTCTTTATAA (9)(SEQ ID NO: 163) Apelin TTCTTCTCAGAGGCCTC (1) (SEQ ID NO: 164) Placentalgrowth factor TAGAGGGGACCCAGTCT (24) (SEQ ID NO: 165) Placental growthfactor CCTTCAATGCAGCCGGG (3) (SEQ ID NO: 166) Placental growth factorGCCTTTCAAGGGGGCAG (1) (SEQ ID NO: 167) PTPRN GGAAGCAGACAGCAGGC (19) (SEQID NO: 168) PTPRN GGCCCCCTCCGGCCCCA* (1) (SEQ ID NO: 169) PTPRNTGATCTCCCAGGAGATG (1) (SEQ ID NO: 170) CD109 GCGACAGTCTCACTCTG (13) (SEQID NO: 171) CD109 TCTCTATATCTCCTTCT (2) (SEQ ID NO: 172) CD109TTACCTCAGTCCAGACA (2) (SEQ ID NO: 173) Progressive ankylosisACTAGAAAATTAAACAG (18) (SEQ ID NO: 174) Collagen VIII, alpha 1TAAAAAAAAGAGAAAAA (14) (SEQ ID NO: 175) Collagen VIII, alpha 1TACAAATAAAAACTAAA (2) (SEQ ID NO: 176) Collagen VIII, alpha 1ATGTACACATACGACGA (1) (SEQ ID NO: 177) Collagen VIII, alpha 1GGATACAATAAATATCC (1) (SEQ ID NO: 178)

Quantitative PCR. mRNA was purified using the Quick Prep Micro mRNApurification kit (Amersham, Piscataway, N.J.). Single-stranded cDNA wasgenerated using Superscript III first strand synthesis system(Invitrogen) following the manufacturer's directions. Quantitative PCRwas performed with an MX4000 using Brilliant SYBR Green QPCR Master Mixand threshold cycle numbers were obtained using MX4000 software v4.20(Stratagene, La Jolla, Calif.). Primer sets for each sequence analyzedare included in Table 5E below. Endothelial cells used in QPCR areprovided in Table 5F. Antibodies against the endothelial selectionmarkers CD105, VE-cadherin (VE-cad) or both were used in the positiveselection to immunopurify the endothelial cells. Endothelial cells werederived from the host strain indicated and then used to generate cDNAfor QPCR. Nude: NCr nu/nu.

TABLE 5E Primer sets for QPCR. SEQ ID NO (Forward, Reverse) Gene ForwardPrimer Reverse Primer Normalizers 179, 180 Snrp70 CTCCTCCTCCAACAAGCGATGAAGGCATAACC AGCAG ACG 181, 182 VE-cadherin GCTACCTGCCCACCATCATCCACTGCTGTCAC CG ACGG Brain endothelial Marker Primers 183, 184Glut-1 ATCCCAGCAGCAAGAA ATCATCAGCATGGAGT GGTG TCCG 185, 186 Oatp2TGGAACTGGAACCAAC AGGTATGGCTCCCAGC ATGG GAG Physiological AngiogenesisMarker Primers 187, 188 Ube2c GTGGGCAAGCGGCTAC CGATGTTGGGTTCTCCT AG AGC189, 190 TRAFaf1 ATCGAGACGAGAGAAT GGAGTCCGTGTGATCT GGGC GTGG 191, 192DNA topo II ACTGCTCCGCCCAGAT CCATAGCCATTTCGAC alpha ACC CACC 193, 194Ckap2 CTCAGCCTATTGAAGA AGCGTCTCACTGGTGT GATGCG CAGG 195, 196 Inhibinbeta- GCGTCTCCGAGATCAT TGACCCGTACCTTCCTC B CAGC CTG 197, 198 ThymidineATCGCCCAGTACAAGT GGAAGGTCCCATCCAG kinase 1 GCC CG 199, 200 Tenascin CTTTGGCTTGGACTGGA TGCCCATCAGGTTGAC TAACC ACG 201, 202 NeurotensinGAAGATGTGAGAGCCC CCTGGATTATCTCCCA TGGAG GTGTTG 203, 204 Prc1CTACACCCAACAGTAG TCCGTCAGTCCAGTCC CATTCG AGG 205, 206 Ki67 antigenCGCACACTTCCCGCTG GCTCGCCTTGATGGTT AG CC 207,208 Integrin betaCGGGATGACATCGAGC ACACTCAGGCTCTTCC 3 AG ACCAC PathophysiologicalAngiogenesis Marker Primers 209, 210 Vscp CCGTCATATTCGCCTGTGCTGGCAGGTGCTCT GG AGG 211, 212 CD276 CTTGTTCGATGTTCACAGCCGTAGAGCTGTCTT GCG GGATC 213, 214 Ets variant AACGAAGTCTCCAAATAGGTGGAATTAGGCCT gene 4 CTGTCC GGG 215, 216 CD137 CAGCATAGGTGGACAGCACACCACGTCCTTCT CCG CCG 217, 218 MiRP2 GGAGACAGATCGTAGAGGAAGCAGCCAGAGTC GGCG GTG 219, 220 Ubiqutin D GTCCGCACCTGTGTTGCATCTTCCAGCTTCTTT TCC CCG 221, 222 Prion-PLP TAGCAGAGAACCGAGAGCTTCAGAGCAGCCTT TTCACC CGTAG 223, 224 Apelin AATCTGAGGCTCTGCGGCCCTTCAATCCTGCTT TGC TAGA 225, 226 Placental GTGCCTTGAAGGACCTAGCAGCCACTACAGCG growth factor TGG ACTC 227, 228 PTPRN GGTGTCGGAGCACATCTCAAACTGGTCCTTAG TGG AACGG 229, 230 CD109 CGGCACTACCTCTGAGAACCTGAATGGACCAG CAGT TCACC 231, 232 Progressive TCACTGGATGGCTGATTGTTGGAGGCATGTCG ankylosis GACAC GTC 233, 234 Collagen TTCCACAGTACCAGCCCTCCACGGGGACCTTG VIII, alpha 1 CTTG TTC

TABLE 5F Endothelial cells for QPCR. Strain Selection Marker Normal ECsBrain Nude CD105 & VE-cad Heart Nude CD105 & VE-cad Kidney Nude CD105Spleen Nude VE-cad Intestine C57BL/6 CD105 Lung Nude CD105 liver NudeCD105 Reg. Liv. Ecs  6 h Nude CD105 18 h Nude CD105 40 h Nude CD105 72 hNude CD105 96 h Nude CD105 Tumor ECs CT26 Balb/c CD105 & VE-cad EMT6Balb/c CD105 & VE-cad KM12SM Nude CD105 & VE-cad LLC C57BL/6 CD105 &VE-cad LS174T Nude CD105 SW620 Nude CD105 & VE-cad

All primers were designed to span large introns thereby preventingpotential amplification of contaminating genomic DNA. Primers were onlyused if they produced a single band of the expected size upon gelelectrophoresis and failed to produce primer dimer products as assessedby gel electrophoresis and melting point analysis on the MX4000.Conditions for amplification were: one cycle of 95° C., 10 min followedby 40 cycles of 95° C., 20 sec, 56° C., 30 sec, and 72° C., 30 sec.Quantitative PCR reactions were performed in duplicate and thresholdcycle numbers were averaged. Gene expression was normalized to that ofthe 70 Kd U1 small nuclear ribonucleoprotein polypeptide A (Srnp70), agene that is uniformly expressed in all ECs as assessed by SAGE.Relative expression was calculated using the formula2^((Rt-Et))/2^((Rn-En)) where Rt is the threshold cycle number observedin the experimental sample for Srnp70, Et is the threshold cycle numberobserved in the experimental sample for the gene of interest (GOI),R_(n) is the average threshold cycle number observed for Srnp70 in allthe N-EC samples and E_(n) is the average threshold cycle numberobserved for the GOI in all the N-EC samples.

In Situ Hybridization. Digoxigenin (DIG)-labeled antisense RNA probeswere generated by PCR amplification of 500-600 basepair productsincorporating T7 promoters into the antisense primers. In vitrotranscription was performed with DIG RNA labeling reagents and T7 RNApolymerase according to the manufacturer's instructions (Roche,Indianapolis, Ind.). Tumors and normal tissues were dissected, embeddedin OCT, frozen in a dry ice-methanol bath, and cryosectioned at 10 μm.All sections were immediately fixed with 4% paraformaldehyde,permeabilized with proteinase K, rinsed with 5×SSC and incubated withRNA probes (100 ng/ml) diluted in ISH solution (Dako, Carpinteria,Calif.) overnight at 55° C. After washing three times with 2×SSC,sections were incubated at 37° C. with RNase Cocktail (Ambion, Austin,Tex.) diluted 1:200 in 2×SSC. Slides were stringently washed twice in2×SSC/50% deionized formamide (American Bioanalytical, Natick, Mass.)and then once with 0.1×SSC at 55° C. Before immunodetection, tissueswere treated with peroxidase blocking reagent (DAKO) and blocked with 1%blocking reagent (Roche) containing purified, nonspecific rabbitimmunoglobulins (DAKO). For signal amplification, a horseradishperoxidase-rabbit anti-DIG antibody (DAKO) was used to catalyze thedeposition of FITC-tyramide (GenPoint Fluorescein kit, DAKO). Furtheramplification was achieved by adding horseradish peroxidase-rabbitanti-FITC (DAKO), biotin-tyramide (GenPoint Kit, DAKO), and thenalkaline phosphatase rabbit anti-biotin (DAKO). Signal was detected withthe alkaline phosphatase substrate Fast Red TR/Napthol AS-MX (SigmaChemical Co., St. Louis, Mo.). Cells were counterstained with a 1/40diluted stock of hematoxylin and mounted with Aqueous Mounting Medium(BioGenex, San Ramon, Calif.).

Immunofluorescent studies. Dual-color immunofluorescence was performedon fresh-frozen sections fixed in Leukoperm (Serotec, Raleigh, N.C.).For CD105 detection, sections were stained with rat anti-mouse CD105followed by FITC-linked goat-anti-rat (Jackson ImmunoresearchLaboratories, West Grove, Pa.) and 488 goat anti-FITC (Invitrogen).VE-cadherin was detected using goat anti-mouse VE-cadherin followed byrhodamine-streptavidin (Vector Laboratories, Burlingame, Calif.). Fordual CD276 and vWF immunofluorescence staining, tissues weresimultaneously stained using a mouse anti-CD276 (R&D) monoclonalantibody and a rabbit anti-vWF polyclonal antibody (Dako). CD276 wasdetected with a FITC-conjugated goat anti-mouse antibody (JacksonImmunoresearch Laboratories) followed by a 488 goat-anti-FITC antibody(Invitrogen) and a 488 donkey anti-goat antibody (Invitrogen). vWF wasdetected using a biotin-linked donkey anti-rabbit antibody (JacksonImmunoresearch Laboratories) followed by rhodamine-streptavidin (VectorLaboratories, Burlingame, Calif.). Images were captured using a NikonEclipse E600 microscope.

Immunohistochemical studies. Paraffin sections were deparaffinized,incubated with proteinase K, heated at 95° C. for 20 min in citratebuffer (pH 6) (Invitrogen), and treated with peroxidase blocking reagent(Dako). Sections were incubated with a biotin-labelled polyclonalantibody against CD276 (R&D) followed by an HRP-conjugated anti-biotinantibody (Dako) and visualized by DAB (diaminobenzidine) staining.Sections were lightly counterstained with hematoxylin.

Immunoblot studies. A CD276 expression vector was made by excising ahuman CD276 cDNA from an EST (accession number BC7472032) using therestriction enzymes EcoR1 and Not1 and cloning the fragment into thesame sites of the expression vector pcDNA3.1 (+) (Invitrogen).Sequencing of the CD276/pcDNA3 vector revealed that it contained a fulllength CD276 cDNA corresponding to transcript variant 1 (accessionnumber NM_(—)001024736). CD276/pcDNA3 was transfected into 293 cellsusing lipofectamine, and stable transfectants selected with Geneticin.To generate extracts for immunoblotting, colorectal tissues stored at−80° C. were thawed, diced with a razor, immediately homogenized in coldTNT buffer [50 mM Tris (pH 7.5), 75 mM NaCl, 1% triton X-100 containinga cocktail of protease inhibitors (Roche)] and clarified bycentrifugation. Protein extracts from tissues or lysed 293 cells wereseparated by SDS-PAGE and transferred to a PDVF membrane (Millipore).Immunoblots were probed with a monoclonal anti-CD276 antibody(eBioscience) or an anti-actin antibody (Chemicon) followed by anHRP-conjugated anti-mouse secondary antibody (Jackson), and visualizedusing the ECL plus system (Amersham) according to the supplier'sinstructions.

Example 2 Purification of Endothelial Cells from Normal and MalignantTissues

This example describes methods used to immunopurify endothelial cells(ECs) from various tissue types.

Initial attempts to purify ECs involved antibody recognition of CD31,the conventional cell surface marker used for affinity purification ofmouse ECs, were difficult because of its cross reactivity withhematopoietic cells. CD105 (endoglin) and/or VE-cadherin were found tobe specifically localized to the ECs of normal and tumor tissues. Forexample, as illustrated in FIG. 1A, immunofluorescence staining of hearttissue demonstrated co-localization of CD105 (green) with VE-cadherin(red) in the heart vessels. Further, FIG. 1B demonstratesimmunofluorscence staining of liver tissue with CD105 (green). CD105 wasdetermined to be a preferred marker in liver because CD105 stained allthe endothelium including sinusoidal ECs whereas VE-cadherin did not.

The cell isolation involved tissue dissociation, the removal of non-ECs,and the positive selection of ECs using magnetic beads coupled to eitheranti-VE-cadherin or anti-CD105 antibodies, the choice depending on thetissue being dissociated (see Example 1, Material and Methods). Toassess the purity of the isolated cells, QPCR analysis was performed oncDNA generated directly from unfractionated normal whole tissues (WT),purified ECs isolated from normal tissues (N-ECs) or ECs isolated fromtumors. As illustrated in FIG. 1C, a marked enrichment ofendothelial-specific genes such as VE-cadherin was found in each of thepurified fractions compared to unfractionated whole tissues, but littlecontamination by hematopoietic cells, as judged by CD45 expression. Forexample, VE-cadherin was enriched 110 to 530-fold in the endothelialfractions. The modest level of VE-cadherin found in the unfractionatedheart and lung sample is presumably due to a higher proportion of ECs inthese tissues. Gene expression was normalized to that of the Eif4h, agene found to be uniformly expressed in all cells as assessed by SAGE(Velculescu et al. Nat. Genet. 23: 387-8, 1999). Unfractionated brainwas used to calibrate relative expression because this tissue had thelowest VE-cadherin expression levels.

FIG. 1D provides a model used to identify genes expressed duringpathological but not physiological angiogenesis. ECs were isolated fromnormal resting livers, regenerating livers, or tumor bearing livers.

Example 3 Identification of Organ-Specific Endothelial Cell Markers

This example illustrates methods used to identify 27 brain and 15 liverspecific endothelial cell markers.

Antibodies against the endothelial selection markers CD105, VE-cadherin(VE-cad) or both were used in the positive selection to immunopurify theendothelial cells. Endothelial cells were derived from the host strainindicated, and the number of SAGE tags obtained for each library isindicated. These SAGE libraries utilized a 21 nucleotide “long tag”which facilitates the mapping of genes directly to genomic DNA even whenEST or cDNA sequence was unavailable (Saha et al., Nat. Biotechnol. 20:508-12, 2002). For SAGE comparisons, all endothelial cell libraries werenormalized to 100,000 tags except for kidney which was normalized to30,000 tags due to the lower number of tags obtained for the kidneyendothelial cell library. As illustrated in Table 6, 700,189 tags wereobtained from these 7 normal EC libraries.

TABLE 6 Identification of 7 normal EC libraries. Strain Selection MarkerNo. Tags Normal ECs Brain C57BL/6 CD105 & VE-cad 168,029 Heart Balb/cCD105 86966 Kidney Nude CD105 29884 Spleen C57BL/6 VE-cad 93150 LungNude CD105 104998 Muscle C57BL/6 CD105 & VE-cad 107,726 Liver Nude CD105109436 Reg. Liv. Ecs 24 h Nude CD105 105,145 48 h Nude CD105 174880 72 hNude CD105 115,209 Tumor Ecs CT26 Balb/c VE-cad 93,981 EMT6 Balb/c CD105& VE-cad 114,910 KM12 Nude CD105 167124 LLC C57BL/6 VE-cad 104,283 SW620Nude CD105 & VE-cad 112312

Analysis of the transcripts revealed the presence of multipleendothelial-specific transcripts, while epithelial, hematopoietic andhepatocyte markers were absent or rare (See Tables 7A and 7B). Tagcounts for endothelial, hematopoietic, epithelial, hepatocyte,pericyte/smooth muscle cell, lymphatic endothelial, and fibroblastsmarkers were obtained by normalizing to 100,000 tags for each of theSAGE libraries shown. The hematopoietic cell fraction (HCF) control wasderived from 53,271 SAGE tags. This SAGE library was constructed fromhematopoietic cells that had been purified from collagenase dispersedKM12SM tumors using a mixture of magnetic beads coupled to anti-F480,anti-CD45, anti-CD68 and anti-CD19 antibodies. The unfractionated(Unfrac.) liver control was derived from 37,162 SAGE tags originatingfrom C57BL/6 whole liver and is publicly available at SAGEmap (WorldWide Web address of ncbi.nlm.nih.gov/projects/SAGE/). The unfractionatedintestine control was derived from 115,942 SAGE tags originating frommicroscope-dissected small intestine of a late gestation embryo alsoavailable at SAGEmap. The endothelial libraries are the same as thosefound in Table 6.

Tables 7A and 7B. Multiple endothelial-specific transcripts in the 7normal EC libraries.

TABLE 7A Endothelial purity in normal endothelial cells and controls.Controls Unfra. Unfra. Normal ECs Liver Intestine HCF Brain Heart KidneyLiver Lung Muscle Spleen Endothelial 5 3 0 77 117 80 74 104 106 9 CD31(PECAM) markers 0 2 0 24 46 30 60 25 24 15 CD105 (Endoglin) 3 1 0 213 3260 33 210 30 37 Claudin 5 8 12 0 46 53 50 55 94 104 14 VE-cadherin 0 2 013 13 50 82 18 21 3 VEGFR2 0 0 0 224 137 10 58 48 72 0 vonWillebrandFactor Hemato- 0 0 15 0 0 0 0 0 0 0 CD18 poietic 0 0 15 0 0 0 0 0 0 0CD45(Ly-5) markers 0 0 43 0 0 0 0 0 0 0 Interleukin 10 0 0 30 0 0 0 0 00 0 Macrophage scavenger Rec. 2 Epithelial 5 19 0 0 0 0 0 1 0 0Cytokeratin 8 markers 0 17 0 0 0 0 0 4 0 0 E-cadherin Hepatocyte 501 0 00 0 0 3 0 0 0 Albumin markers 414 0 0 0 0 0 0 0 0 0 Fibrinogen, B betaPericyte/ 0 2 2 2 1 3 0 0 0 0 NG2 (Cspg4) SMC 0 24 0 1 1 0 0 0 0 0Calponin-1 markers Lymphatic 0 1 0 1 0 0 0 6 0 0 Podoplanin endothelial0 1 0 0 2 0 0 0 2 4 Prox-1 markers Fibroblast 0 3 0 0 0 0 0 0 1 0Fibroblast Activation Protein markers

TABLE 7B Endothelial purity in regenerativing liver endothelial cellsand tumor endothelial cells Reg. Liver ECs Tumor ECs 24 hr 48 hr 72 hrCT26 EMT6 KM12SM LLC SW620 Endothelial 95 90 69 85 77 34 151 82 CD31(PECAM) markers 40 50 37 10 22 20 15 22 CD105 (Endoglin) 16 13 20 35 3713 62 22 Claudin 5 46 51 52 63 50 28 116 58 VE-cadherin 12 45 38 21 1417 9 29 VEGFR2 133 58 45 56 23 25 52 36 vonWillebrand Factor Hemato- 1 02 1 1 0 0 0 CD18 poietic 0 0 2 0 0 0 1 0 CD45(Ly-5) Markers 0 0 2 0 0 00 0 Interleukin 10 0 0 0 0 0 0 0 0 Macrophage scavenger Rec. 2Epithelial 0 0 0 0 3 0 0 0 Cytokeratin 8 Markers 0 0 0 0 0 0 0 0E-cadherin Hepatocyte 0 3 2 0 0 1 0 0 Albumin markers 0 0 0 0 0 0 0 0Fibrinogen, B beta Pericyte/ 0 1 1 0 1 1 0 0 NG2 (Cspg4) SMC 0 0 0 0 0 20 2 Calponin-1 markers Lymphatic 1 0 0 2 4 2 0 0 Podoplanin endothelial0 0 1 0 0 0 0 0 Prox-1 markers Fibroblast 0 0 0 0 1 1 0 1 FibroblastActivation Protein markers

Brain Endothelial Markers (BEMs) were defined as genes that wereexpressed 20-fold or higher in brain compared to all other normalendothelium (see Table 8, below). The most abundant and differentiallyexpressed gene identified was the brain glucose transporter Glut-1, ablood-brain barrier (BBB) marker previously found to be expressed on theluminal surface of brain endothelium (Farrell & Pardridge, Proc. Natl.Acad. Sci. U.S.A. 88:5779-83, 1991; Pardridge et al. J. Biol. Chem.265:18035-40, 1990). Thirteen of the 27 BEMs (˜50%) appear to reside atthe cell surface and at least 9 of these are transporters potentiallyinvolved in BBB function. Seven of the BEMs, including five cell surfacetransporters, were previously localized to brain endothelium by in situstaining. Some of the cell surface transporters have also beenidentified in liver tissues where they appear to be expressedpredominantly by hepatocytes or other non-ECs (Gu et al. Proc. Natl.Acad. Sci. U.S.A. 97:3230-5, 2000; Konig et al. Am. J. Physiol.Gastrointest. Liver Physiol. 278:G156-64, 2000; and Mesli et al. Eur. J.Biochem. 271:3103-14, 2004). Intracellular enzymes, such asglutathione-S-transferase alpha 4 (Gsta4), were also identified whichmay be involved in protecting the brain from toxic chemicals that enterthe blood.

Liver Endothelial Markers (LEMs) were defined as genes that wereexpressed 20-fold or higher in liver compared to all other normalendothelium (Table 8). The most highly expressed gene wasdeoxyribonuclease 1-like 3, a recently identified nuclease that may beinvolved with chromatin clearance from the circulation (Napirei et al.Biochem. J. 389:355-64, 2005). CD32 is a low affinity Fc γ-receptor thatis a known marker of liver sinusoidal ECs (Muro et al. Am. J. Pathol.143:105-20, 1993). Two lectin-like receptors, one of which was shownrecently to be expressed predominantly by sinusoidal ECs of human liverand lymph node (Liu et al. J. Biol. Chem. 279:18748-58, 2004) were alsoidentified. Seven of the LEMs identified appear to reside at the cellsurface, including three that have not yet been characterized. Theseresults highlight the complexity of blood vessels and demonstrate theexistence of multiple organ-specific endothelial markers in differenttissues.

TABLE 8 Organ-specific endothelial cell markers. GenBank Brain HeartKidney Liver Lung Muscle Spleen Acc.# Description* Brain endothelialmarkers 1 754 8 1 2 1 12 4 NM_011400 GLUT-1 2 157 0 0 0 0 1 0 NM_030687Organic anion transporter 2 3 93 0 1 0 0 1 1 NM_008973 Pleiotrophin 4 320 0 0 0 0 0 NM_009728 ATPase, class V, type 10A 5 40 0 0 0 1 0 0NM_009402 Peptidoglycan recognition protein 1 6 26 0 0 0 0 0 0 NM_021471Organic anion transp. 14 7 29 0 0 0 0 0 0 NM_008239 Forkhead box Q1 8 190 0 0 0 0 0 NM_031194 Organic anion transporter 3 9 73 0 0 0 3 0 0NM_172479 SN2, Solute carrier family 38, member 5 10 40 0 0 0 1 2 0NM_172471 Inter-alpha (globulin) inhibitor H5 11 12 0 0 0 0 0 0NM_010703 Lymphoid enhancer binding factor 1 12 23 0 0 0 0 0 1 NM_011404Slc7a5 aa transporter 13 20 1 0 0 0 0 0 NM_023805 Solute carrier family38, member 3 14 17 0 0 0 0 0 0 NM_009574 Zinc finger protein of thecerebellum 2 15 81 6 0 0 1 3 0 NM_052994 Testican-2 16 26 0 1 0 1 1 0NM_008256 3-HMG-CoA synthase 2 17 15 0 0 0 0 0 0 NM_028748 Progestin andadipoQ receptor family member V 18 68 0 1 2 1 0 1 AK172004 APCdown-regulated 1, Drapc1 19 13 0 0 1 0 0 0 NM_027096 Unknown, GDPDphosphodiesterase family 20 26 0 0 3 1 0 0 NM_029001 Unknown, putativetransmembrane protein 21 19 1 0 0 0 1 0 NM_027299 DES2, lipiddesaturase/C4-hydroxylase 22 39 0 1 0 2 0 1 XM_486083 Unknown, kelchrepeat and BTB (POZ) domain 23 46 2 1 0 1 1 0 NM_017405 Lipolysisstimulated receptor 24 36 2 0 0 1 1 0 NM_010357 GlutathioneS-transferase, alpha 4 25 9 0 0 0 1 0 0 NM_013869 TNF receptorsuperfamily, member 19 26 17 1 0 0 0 1 0 NM_011532 T-box 1 27 6 0 0 0 10 0 XM_620023 Unknown, putative transmembrane protein Liver endothelialmarkers 1 0 0 0 196 0 0 0 NM_007870 Deoxyribonuclease 1-like 3 2 0 0 058 0 0 3 NM_010959 LZP, oncoprotein induced transcript 3 3 0 0 0 16 0 00 NM_023438 Unknown^(‡), putative transmembrane protein 4 1 0 0 123 0 06 AK150613 CD32 5 0 1 0 33 0 1 1 NM_033616 Unknown, putative G-proteincoupled receptor 6 0 1 0 14 0 0 0 NM_019985 C-type lectin-like receptor2 7 0 0 0 216 0 0 24 NM_029465 Clec4g (LSECtin) 8 0 1 0 42 2 1 0NM_018797 Plexin C1 9 0 1 0 9 0 0 0 NM_011719 Wnt9B 10 1 0 0 16 1 0 0AK144596 Unknown 11 0 1 0 9 0 0 0 NM_008092 GATA-binding protein 4 12 00 0 10 1 2 0 AB049755 MBL-associated serine protease-3 13 0 0 0 5 0 0 1NM_023132 Renin binding protein 14 0 0 0 16 1 2 1 NM_144830 Unknown,putative transmembrane protein 15 1 0 1 11 0 0 0 NM_011243 Retinoic acidreceptor, beta

Example 3 Gene Expression in Resting Normal ECs, Regenerating Liver ECsand Tumor ECs

This example illustrates the expression of various markers in restingnormal ECs, regenerating liver ECs and tumor ECs.

In order to identify genes that were elevated during physiologicalangiogenesis, ECs were isolated from liver at 24-, 48- or 72-hoursfollowing partial hepatectomy, the period during which endothelialgrowth is thought to occur (Michalopoulos & DeFrances. Science276:60-66, 1997). In total, 395,234 SAGE tags were isolated fromregenerating liver (See Table 6). Gene expression patterns ofregenerating liver ECs were compared with a combined set of EC librariesderived from all non-proliferating normal organs including resting liver(see FIG. 1D). This comparison revealed 12 genes that were overexpressedin regenerating liver ECs compared to non-angiogenic ECs (Table 9),which were referred to as physiological angiogenesis endothelialmarkers.

At least seven of these genes may be involved in regulating progressionthrough the cell cycle, consistent with the fact that these ECs aredividing. For example, the most abundant physiological angiogenesismarker is an ubiquitin-conjugating enzyme, Ube2c. Its human counterpart,UbcH10, is involved in progression through the G1 phase of the cellcycle (Townsley et al. Proc. Natl. Acad. Sci. U.S.A. 94:2362-7, 1997;and Rape & Kirschner. Nature 432:588-95, 2004). Protein regulator ofcytokinesis 1 (PRC1) is a mitotic spindle-associated CDK substrate thatis involved in cytokinesis (Jiang et al. Mol. Cell. 2:877-85, 1998). DNAtopoisomerase II-alpha (Top2a), Thymidine Kinase 1 (TK1) and the Ki67antigen are markers of proliferating cells (Gerdes et al. J. Immunol.133: 1710-1715, 1984; Sampson et al. J. Pathol. 168: 179-185, 1992; andBradshaw Proc. Natl. Acad. Sci. U.S.A. 80:5588-91, 1983). Oneextracellular matrix glycoprotein, Tenascin C, is frequently associatedwith angiogenesis of malignant tumors, inflamed tissues and healingwounds (Tanaka et al. Int. J. Cancer 108: 31-40, 2004; and Zagzag et al.Cancer Res. 56: 182-9, 1996). The only physiological angiogenesisendothelial marker identified encoding a predicted cell surface productwas integrin β3, a receptor that partners with integrin αv and isthought to regulate angiogenesis (Brooks et al. Science 264:569-71,1994).

TABLE 9 Physiological and Pathological Angiogenesis Endothelial CellMarkers. Normal resting ECs Reg. Liver ECs Tumor ECs Brain Heart KidneyLiver Lung Muscle Spleen 24 h 48 h 72 h CT26 EMT KM LLC SW GenBank Acc.# Description Physiological Angiogenesis Markers 0 0 0 0 0 0 0 0 10 14 53 4 9 0 NM_026785 Ube2c* 0 0 0 0 0 0 0 1 5 11 0 5 2 3 2 NM_026412TRAF4af1 0 0 0 1 1 0 0 0 17 16 5 8 3 11 10 NM_011623 DNA topo IIα* 0 0 00 0 0 0 0 4 3 3 2 2 8 0 NM_001004140 Ckap2* 1 1 0 1 0 2 0 19 11 3 31 2814 20 11 NM_008381 Inhibin beta-B 0 0 0 1 0 0 0 0 4 6 5 6 5 5 7NM_025415 Cks2* 1 0 0 1 0 0 0 4 13 12 7 6 1 8 5 NM_009387 TK1* 0 0 0 0 12 0 0 2 6 5 14 16 24 12 NM_011607 Tenascin C 0 3 0 0 0 0 0 5 3 3 5 5 3 91 NM_024435 Neurotensin 0 0 0 1 1 0 0 0 5 10 5 3 4 10 0 NM_145150 Prc1*0 0 0 0 1 1 2 0 11 12 7 7 2 5 4 XM_133912 Ki67 antigen* 0 1 0 1 0 1 1 35 3 17 10 6 4 9 NM_016780 Integrin-β3^(†) Pathological AngiogenesisMarkers 0 0 0 0 1 0 0 1 1 1 7 11 0 26 4 DQ832275 Vscp 0 1 0 0 0 0 0 0 10 1 6 3 10 16 DQ832276 CD276^(†) (B7-H3) 0 0 0 0 1 0 0 0 0 1 6 4 5 9 12DQ832277 ETSvg4 (Pea3) 0 1 0 0 0 0 0 0 0 0 8 2 1 26 3 DQ832278^(||)CD137^(†) (4-1BB) 0 2 1 0 0 0 1 0 0 0 15 5 19 8 37 DQ832280 MiRP2^(†) 00 0 0 0 0 0 0 0 0 3 5 0 2 1 NM_023137 Ubiquitin D (FAT10) 0 0 0 0 0 1 10 0 0 1 3 0 17 5 DQ832281 Doppel^(†) (Prion-PLP) 0 0 1 0 1 0 0 0 0 0 0 62 7 7 DQ832282 Apelin 1 1 1 0 0 0 0 0 0 0 2 10 4 5 7 NM_008827 Plgf 0 10 0 1 0 0 0 0 0 14 1 1 5 0 DQ832283 Ptprn^(†) (IA-2) 0 0 1 0 0 0 0 1 0 10 6 3 7 1 DQ832284 CD109^(†) 1 0 0 0 0 0 0 2 1 0 10 1 1 5 1 DQ832285Ankylosis^(†) 0 0 1 0 1 0 0 1 0 0 3 2 8 1 5 NM_007739 Coll. VIII, α1*Genes encoding products thought to be important in cell cycle control^(†)Encodes known or predicted cell surface protein ^(‡)Gene name isgiven followed by alternative names in parenthesis ^(||)The Genbankaccession number for the secreted variant sCD137 is DQ832279

Gene expression was evaluated by real-time QPCR and compared with thatof Srnp70, a gene expressed at nearly identical levels in all ECs, bySAGE. Organic-anion-transporter 2 (Oatp2) is a BEM, Ube2c, TRAFaf1, andDNA topoisomerase IIα (Top2a) are physiological angiogenesis markers,and Vscp, CD276, Ptprn and CD137 are pathological angiogenesis markers.For physiological and pathological angiogenesis markers, the results areexpressed as the ratio between the gene of interest and Srnp70expression and are normalize to the average expression in allnon-angiogenic normal ECs. For Oatp2, samples were normalized to theaverage expression in intestinal, heart and kidney ECs. For comparison,normal ECs from resting liver (time=zero hours) were grouped with theregenerating liver ECs.

QPCR analysis confirmed that each of the physiological angiogenesismarkers (Table 9) were induced in the regenerating liver ECs, with peaklevels ranging from 15- to 100-fold over non-proliferating ECs (FIGS. 2Aand 2B). All of the physiological angiogenesis markers genes identifiedwere also found to be overexpressed in tumor endothelial cells (seeTable 9), providing further evidence that expression of these genes isupregulated during angiogenesis. Although most of the genes displayedmaximum mRNA expression at 72 hours, the genes encoding inhibin-beta Band α3-integrin reached their peak expression levels by 6 hours. Suchearly endothelial response genes may be important upstream regulators ofthe angiogenic cascade.

Each of the disclosed pathological angiogenesis genes detected by QPCRhad a similar pattern of expression to that predicted by the SAGEanalysis, with levels of expression barely detectable in regeneratingliver endothelium (FIG. 2A and FIG. 2C). Most of the genes wereoverexpressed in the ECs of all of the tumors examined, although 6 ofthe genes (Ankylosis, Apelin, MiRP2, CD109, Doppel and Ubiquitin D) wereoverexpressed in the vessels of only a subset of the tumor types.Ubiquitin D was only expressed in the vessels of mouse tumors (CT26,EMT6 and LLC), but was essentially undetectable by QPCR in tissueculture-derived tumor cells.

RT-PCR was used to verify that Ubiquitin D is expressed by the tumorendothelial cells (TECs) and not the tumor cells themselves. To generatecDNA for RT-PCR, mRNA was extracted from CT26, EMT6 and LLC tumor celllines grown in tissue culture, the corresponding tumor cells isolatedfrom tumors grown in vivo, or the corresponding TECs isolated from thesame tumors. To isolate tumor cell-enriched fractions in vivo, tumorswere dispersed with collagenase and endothelial cells and hematopoieticcells were removed using magnetic dynabeads coupled to CD105 and CD45.Tumor endothelial cells were isolated as described in the Examples (suchas Example 1). PCR amplification of VE-cadherin was used as a control toverify the endothelial origin of the purified tumor endothelial cells,and β-actin was used as housekeeping control to ensure the presence ofsimilar amounts of template in each of the samples. As illustrated inFIG. 7, Ubiquitin D mRNA was essentially undetectable when RT-PCR wasperformed on in vivo tumor cell-enriched fractions or the tumor celllines grown in tissue culture indicating that such expression is not dueto the presence of contaminating tumor cells.

Example 4 Pathological Angiogenesis Endothelial Marker Genes Identifiedby SAGE are Expressed by ECs in Tumor Vessels In Vivo

This example demonstrates that the tumor endothelial marker genesidentified by SAGE (Example 1) are expressed by ECs in tumor vessels invivo. To exclude the possibility that the differentially expressedtranscripts were derived from other contaminating non-ECs, mRNA in situhybridization studies using a highly sensitive non-radioactive techniquewere performed (FIG. 3, FIG. 9A, FIG. 9B and Table 10).

Table 10 illustrates in situ hybridization results of BEMs and LEMs innormal adult brain and liver tissues. Expression of BEM or LEM mRNA wasanalyzed in resting adult brain and liver tissues and scored as negative(−), moderately positive (+), moderate to strongly positive (++) orstrongly positive (+++) based on the staining intensity of endothelialcells. In these experiments, brain and liver tissues were placed next toeach other in frozen tissue blocks so that the two tissues could besectioned together and processed simultaneously. Four brain endothelialmarkers were localized to ECs throughout the brain whereas expression inliver was undetectable (Table 10). Similarly, an analysis of five liverendothelial markers revealed that each was readily detectable in liverendothelium but not brain endothelium. Liver endothelial markers wereexpressed predominantly in the sinusoidal ECs with a pattern of stainingsimilar to that of the endothelial control VEGFR2 (Table 10). However,LEM5, a previously uncharacterized putative G-protein coupled receptor,was also found in the larger vessels of central veins, portal veins andhepatic arteries

TABLE 10 In situ hybrization of brain endothelial markers and liverendothelial markers in normal adult brain and liver tissues. Liver largeLiver capillaries vessel ECs^(†) (Sinusoidal (CV, Brain ECs) PV & HA)ECs Controls CD31 + +++ + VEGFR2 +++ − ++ Brain BEM1 (GLUT-1) − − +++Endothelial BEM2 (Oat2) − − ++ Markers BEM3 (Ptn) − − ++^(§) BEM4(Atp10a) − − + Liver LEM1 Endothelial (Dnase113) +++ − − Markers LEM2(Oit3) +++ − − LEM5 (Csprs) ++ ++ − LEM6 (Clec1b) + − − LEM8 (Plxnc1)+++ − −* ^(†)CV: central vein; PV: portal vein; HA: hepatic artery^(§)Pericytes appear to be responsible for predominant staining of bloodvessels and neuronal cells are also positive. *Negative for blood vesselstaining but some neuronal cells are positive.

Localization of mRNA in ECs (red stain) was demonstrated by examiningOatp2, a representative brain endothelial marker in brain tissue (FIG.3, panel a), and various tumor endothelial markers in tumor tissuesincluding CD276, ETSvg4, Apelin, CD109, MiRP2, CD137, Doppel and Vscp,as illustrated in FIG. 3 panel b through i, respectively. Panels (b) and(c) depict HCT116 tumors grown subcutaneously, FIGS. 3D-3F depict SW620tumors grown subcutaneously, and FIGS. 3G and 3F depict KM12 tumorsgrown in the liver. A dilute counterstain was applied to the sections tohighlight the lack of detectable expression in the non-ECs of thetumors. These signals were specific because their patterns matched thoseobserved with endothelial control probes such as VE-cadherin and vonWillebrand factor (vWF), and omission of the antisense riboprobes orsubstitution with a sense control resulted in a loss of signal in eachcase. The data demonstrate that the disclosed tumor endothelial markersare expressed predominantly by the vessels within each of the tumors.

Example 5 Co-Localization of CD276 with vWF in Human Colon Cancer

This example illustrates that the differential expression of CD276 (atumor endothelial marker) is maintained at the protein level in humancolorectal cancer and demonstrates that CD276 can be used fortumor-specific vascular targeting.

To demonstrate that protein expression patterns of the disclosed tumorendothelial markers followed mRNA expression patterns,co-immunofluorescence studies with antibodies against CD276, the mostdifferentially expressed cell surface receptor identified, and theendothelial marker vWF were performed using 6 normal and 6 malignantcolorectal tissues. As illustrated in FIG. 4A, CD276 was expressedpredominantly by the tumor vessels of the colorectal cancer, but wasalso expressed at a lower level by the tumor cells themselves.Expression of CD276 in normal colonic mucosa was undetectable (topmiddle panel). As a control, vessels were stained for vWF, whichco-localized with CD276 only in the tumor sample.

The human corpus luteum was stained to determine if the normalangiogenic vessels of this tissue express CD276. Unlike the vWF control,CD276 expression was undetectable in the angiogenic vessels of thedeveloping corpus luteum (see FIG. 4B). Sections were counterstainedwith DAPI (left panels of FIG. 4B) to highlight the epithelial cells.

These results demonstrate that the differential expression of CD276 ismaintained at the protein level in human colorectal cancer and indicatethat CD276 is a useful target for tumor-specific vascular targeting.

Example 6 mRNA is Expressed in Human Colorectal Cancer Vessels

This example illustrates that CD276 mRNA is expressed in humancolorectal cancer and indicates that CD276 can be used fortumor-specific vascular targeting.

Riboprobes against human CD276 were generated and mRNA in situhybridization on normal and malignant colorectal tissues was performed.

As shown in FIG. 5, CD276 mRNA was most prominent in the tumor vessels,with a pattern of expression similar to that of the endothelial controlVEGFR2 (left panel). CD276 expression was also detected in the tumorcells themselves, albeit at a lower level. In contrast, CD276 expressionwas undetectable in normal colonic mucosa, and an analysis of the tumormargin showed a striking on/off pattern of staining at the tumor/normalborder (FIG. 5, right panel). For instance, the margin between tumor (T)tissue and normal (N) colonic mucosa CD276 staining abruptly ends (rightpanel). Further, extracellular staining around the normal crypts wasobserved and represents non-specific binding of the in situhybridization reagents to the mucous (right panel); similar staining wasalso detected in control sections.

These results demonstrate that CD276 mRNA is expressed in humancolorectal cancer and indicate that CD276 is a target for tumor-specificvascular targeting.

Example 7 CD276 Protein is Overexpressed in Human Tumors

This example illustrates that CD276 is overexpressed in human tumors andindicates that CD276 is a target for tumor-specific vascular targeting.

CD276 protein expression patterns were evaluated using anti-CD276antibodies. The overall level of CD276 was assessed in extracts takenfrom 12 normal and 12 malignant colorectal tissues, 10 of which werederived from the same patient (P1-P10). As shown in FIG. 6A, CD276 wasclearly elevated in 11 of the 12 tumors, while the remaining matchednormal/tumor pair (case P7) displayed unaltered expression. CD276protein migrated at a size similar to that observed in 293 cellstransfected with the 4IgG-containing form of CD276 (293/CD276). Thefaint product present in 293 parent cells may represent low-levelendogenous CD276 expression which was also detected at the mRNA level inthese cells by RT-PCR.

CD276 protein expression levels were assessed in 6 lung tumor samples.As illustrated in FIG. 6B, CD276 protein expression levels wereincreased in each of the lung tumor samples as compared with proteinlevels detected in patient-matched control samples. All tumor samplesappeared to overexpress the predominant 4-IgG form of CD276, asexogenous overexpression of this form in transfected 293 cells resultedin a product of similar size (FIG. 6A).

To determine the cellular source of this up-regulated protein,immunohistochemistry was performed on paraffin sections obtained from 10patient-matched samples of normal colonic mucosa and colorectal cancer.Ten patient-matched samples of non-small cell lung cancer were alsoanalyzed along with adjacent normal lung tissue. All samples representeddifferent cases than those used for the western analysis. Staining witha CD276 polyclonal antibody revealed a vessel-like pattern in all casesof human colorectal or lung cancer analyzed, but not in matched normaltissues (FIGS. 6C-6H and Table 11).

Moreover, this vessel-like pattern of staining was also observed in eachof a smaller number of breast, esophageal and bladder cancers, but notin corresponding normal tissues (FIGS. 6I-6L). Similar expressionpatterns were observed using an independent monoclonal antibody. CD276overexpression was frequently detected in the tumor cells while normalepithelium was uniformly negative. The highest tumor-cell expressionlevels of CD276 were found in lung and breast cancer where they matchedthat found in tumor endothelium (FIGS. 6F, 6G and 6L). These resultsdemonstrate that CD276 protein is overexpressed in multiple types ofhuman tumors and demonstrate that CD276 is a target for tumor-specificvascular targeting.

TABLE 11 Immunohistological staining of CD276 in normal and tumortissues. Epithelial/tumor Vessel staining^(†) cell staining Normal TumorNormal Tumor Colon 0/10 10/10 0/10  0/10* Lung 0/10 10/10 0/10  5/10Breast 0/3  3/3 0/3  3/3 Bladder 0/2  3/3 0/2  3/3 Esophagus 4/4 1/4*CD276 immunoreactivity in the tumor cells was considered negative inall colon samples by IH because expression levels were close tobackground, but could be detected in the same cells using a moresensitive IF protocol (see FIG. 4). ^(†)Vessel staining refers to thatwhich lines the inner surface of vessels as shown in FIG. 6. Occasionalstaining of the outer adventitia was also observed in some larger bloodvessels, particularly in lung tissues, but is not included here. Allnormal tissue used was patient-matched to the tumor samples. Vesselsfrom normal tissues that failed to stain for CD276 were immunoreactiveon control sections stained for endothelial proteins such as vWF.

Example 8 Inhibition of Pathological Angiogenesis to Treat a Tumor

This example describes methods that can be used to significantly reducepathological angiogenesis, for example as a means to treat a tumor, suchas cancer. One skilled in the art will appreciate that similar methodscan be used with any of the pathological angiogenesis inhibitors shownin Table 9 to treat any tumor that expresses the target angiogenesisprotein.

Based upon the teaching disclosed herein, pathological angiogenesis canbe reduced or inhibited by administering a therapeutically effectiveamount of a composition, wherein the composition includes a specificbinding agent that preferentially binds to one or more pathologicalangiogenesis marker proteins comprising Vscp, CD276, ETSvg4 (Pea3),CD137(4-1BB), MiRP2, Ubiquitin D (Fat10), Doppel (prion-PLP), Apelin,Plgf, Ptprn (IA-2), CD109, Ankylosis, and collagen VIIIα1, therebyinhibiting pathological angiogenesis in the subject.

In an example, a subject who has been diagnosed with a diseaseassociated with or caused by pathological angiogenesis such as a tumoris identified. Following subject selection, a therapeutic effective doseof the composition including the specific binding agent is administeredto the subject. For example, a therapeutic effective dose of a specificbinding agent to one or more of the disclosed pathological angiogenesismarkers is administered to the subject to inhibit pathologicalangiogenesis. In a further example, the specific binding agent is anantibody conjugated to a therapeutic molecule (such as therapeuticmolecule is a cytotoxin, chemotherapeutic reagent, radionucleotide or acombination thereof). The amount of the composition administered toprevent, reduce, inhibit, and/or treat pathological angiogenesis or acondition associated with it depends on the subject being treated, theseverity of the disorder, and the manner of administration of thetherapeutic composition. Ideally, a therapeutically effective amount ofan agent is the amount sufficient to prevent, reduce, and/or inhibit,and/or treat the disorder (e.g., cancer) in a subject without causing asubstantial cytotoxic effect in the subject.

In one specific example, naked antibodies are administered at 5 mg perkg every two weeks or 10 mg per kg every two weeks depending upon thecancer. In an example, the antibodies are administered continuously. Inanother example, antibodies or antibody fragments conjugated tocytotoxic agents (immunotoxins) are administered at 50 μg per kg giventwice a week for 2 to 3 weeks.

Example 9 Screening of Subjects for Pathological Angiogenesis

According to the teachings herein, pathological angiogenesis can bescreened for by detecting at least one expression product comprising oneor more of: Vscp, CD276, ETSvg4 (Pea3), CD137(4-1BB), MiRP2, Ubiquitin D(Fat10), Doppel (prion-PLP), Apelin, Plgf, Ptprn (IA-2), CD109,Ankylosis, and collagen VIII, 1, in a sample obtained from the subjectand compared to a control (sample obtained from a subject withoutpathological angiogenesis) or reference value. In one example, detectionof the at least one expression product indicates pathologicalangiogenesis in the subject. In a further example, detection of the atleast one expression product indicates the presence of a tumor such ascancer. The expression product can be RNA or protein. An RNA expressionproduct can be detected by SAGE or PCR by methods described above (see,for example, Example 1). A protein expression product can be detected byWestern blot or immunoassay (see, for example, Example 1). However, thedisclosure is not limited to particular methods of detection.

Example 10 Delivering a Therapeutic Agent to Organ-Specific Cells

Based upon the teaching disclosed herein, a therapeutic agent can bedelivered to organ-specific cells by administering a therapeuticallyeffective amount of a composition, wherein the composition includes abinding agent that preferentially binds to one or more of the disclosedbrain endothelial marker proteins or liver endothelial markers and thetherapeutic agent, thereby evoking a therapeutic response in theorgan-specific endothelial cells. The one or more brain endothelialmarkers can include Glucose transporter GLUT-1, Organic aniontransporter 2, Pleiotrophin, ATPase class V, type 10A, Peptidoglycanrecognition protein 1, Organic anion transporter 14, Forkhead box Q1,Organic anion transporter 3, SN2 (Solute carrier family 38, member 5),Inter-alpha (globulin) inhibitor H5, Solute carrier 38 member 3, Zincfinger protein of the cerebellum 2, Testican-2,3-HMG-CoA synthase 2,Progestin and adipoQ receptor family member V, APC down-regulated 1Drapc1, GDPD phosphodiesterase family Accession No. NM_(—)001042671,putative transmembrane protein Accession No. NM_(—)029001, DES2 lipiddesaturase/C4-hyroxylase, Kelch repeat and BTB (POZ) domain, Lipolysisstimulated receptor, Glutathione S-transferase alpha 4, TNF receptorsuperfamily member 19, T-box 1 or putative secreted protein AccessionNo. XM_(—)620023. The one or more liver endothelial markers can includeliver endothelial marker proteins such as deoxyribonuclease 1-like 3,LZP oncoprotein induced transcript 3, putative transmembrane proteinAccession No. NM_(—)023438, CD32 15, putative G-protein coupled receptorNM_(—)033616, C-type lectin-like receptor 2, C-type lectin domain family4 member g 16, Plexin C1, Wnt9B, Accession No. AK144596, GATA-bindingprotein 4, MBL-associated serine protease-3, Renin binding protein,putative transmembrane protein Accession No. NM_(—)144830, or Retinoicacid receptor, beta.

In an example, a subject who is in need of delivery of a therapeuticagent to either a brain endothelial cell or a liver endothelial cell isidentified. Following subject selection, a therapeutic effective dose ofthe composition including the specific binding agent is administered tothe subject. For example, a therapeutic effective dose of a specificbinding agent to one or more of the disclosed pathological angiogenesismarkers is administered to the subject to inhibit tumor growth in thebrain or liver. The specific binding agent can be an antibody to one ormore of the organ-specific endothelial markers in which the antibody isconjugated to the therapeutic agent such as a cytotoxin,chemotherapeutic reagent, radionucleotide or a combination thereof.

In view of the many possible embodiments to which the principles of thedisclosure may be applied, it should be recognized that the illustratedexamples are only examples of the disclosed matter and should not betaken as limiting the scope of the disclosure. Rather, the scope of thedisclosure is defined by the following claims. We therefore claim as ourinvention all that comes within the scope and spirit of these claims.

1. A method of inhibiting pathological angiogenesis in a subject,comprising: administering to the subject a therapeutically effectiveamount of a composition, wherein the composition comprises a specificbinding agent that preferentially binds to one or more pathologicalangiogenesis marker proteins comprising Vscp, CD276, ETSvg4 (Pea3),CD137(4-1BB), MiRP2, Ubiquitin D (Fat10), Doppel (prion-PLP), Apelin,Plgf, Ptprn (IA-2), CD109, Ankylosis, and collagen VIIIα1, therebyinhibiting pathological angiogenesis in the subject.
 2. The method ofclaim 1, wherein the one or more pathological angiogenesis markerproteins is Vscp, CD276, MiRP2, Ptprn (IA-2), or ankylosis.
 3. Themethod of claim 1, wherein the specific binding agent significantlyreduces the biological activity of the one or more pathologicalangiogenesis marker proteins.
 4. The method of claim 1, wherein thespecific binding agent further comprises a therapeutic molecule.
 5. Themethod of claim 4, wherein the specific binding agent is an antibody toone or more of the pathological angiogenesis marker proteins conjugatedto the therapeutic molecule, and wherein the therapeutic moleculecomprises a cytotoxin, chemotherapeutic reagent, radionucleotide, orcombination thereof.
 6. (canceled)
 7. The method of claim 1, whereininhibiting pathological angiogenesis treats a tumor, and the compositionincludes a specific binding agent that preferentially binds to one ormore of: Vscp, CD276, ETSvg4 (Pea3), MiRP2, Ubiquitin D (Fat10), Doppel(prion-PLP), Apelin, Plgf, Ptprn (IA-2), CD109, Ankylosis, or collagenVIII.
 8. The method of claim 7, wherein the specific binding agent is anantibody to one or more of: Vscp, CD276, ETSvg4 (Pea3), MiRP2, UbiquitinD (Fat10), Doppel (prion-PLP), Apelin, Plgf, Ptprn (IA-2), CD109,Ankylosis, or collagen VIII conjugated to a therapeutic moleculecomprising a cytotoxin, chemotherapeutic reagent, radionucleotide, orcombination thereof.
 9. (canceled)
 10. The method of claim 8, whereinthe composition includes a specific binding agent that preferentiallybinds to one or more of Vscp, CD276, MiRP2, Ptprn (IA-2), or ankylosis.11. A method of screening for pathological angiogenesis in a subject,comprising: detecting at least one expression product comprising one ormore of: Vscp, CD276, ETSvg4 (Pea3), CD137(4-1BB), MiRP2, Ubiquitin D(Fat10), Doppel (prion-PLP), Apelin, Plgf, Ptprn (IA-2), CD109,Ankylosis, and collagen VIII, 1, in a sample obtained from the subject,wherein detection of the at least one expression product indicatespathological angiogenesis in the subject.
 12. The method of claim 11,wherein the at least one expression product is Vscp, CD276, MiRP2, Ptprn(IA-2), or ankylosis.
 13. The method of claim 11, wherein detection ofthe at least one expression product indicates the presence of a tumor.14. The method of claim 13, wherein the expression product is RNA or aprotein. 15.-16. (canceled)
 17. The method of claim 13, wherein thetumor is a cancer of the colon, liver, lung, or breast.
 18. (canceled)19. The method of claim 11, wherein the detecting the expression productis performed using serial analysis gene expression (SAGE), polymerasechain reaction, Western blot, or immunoassay.
 20. (canceled)
 21. Amethod of delivering a therapeutic agent to brain endothelial cells,comprising: administering a therapeutically effective amount of acomposition, wherein the composition comprises a therapeutic agent and abinding agent that preferentially binds to one or more brain endothelialmarker proteins comprising Glucose transporter GLUT-1, Organic aniontransporter 2, Pleiotrophin, ATPase class V, type 10A, Peptidoglycanrecognition protein 1, Organic anion transporter 14, Forkhead box Q1,Organic anion transporter 3, SN2 (Solute carrier family 38, member 5),Inter-alpha (globulin) inhibitor H5, Solute carrier 38 member 3, Zincfinger protein of the cerebellum 2, Testican-2,3-HMG-CoA synthase 2,Progestin and adipoQ receptor family member V, APC down-regulated 1Drapc1, GDPD phosphodiesterase family Accession No. NM_(—)001042671,putative transmembrane protein Accession No. NM_(—)029001, DES2 lipiddesaturase/C4-hyroxylase, Kelch repeat and BTB (POZ) domain, Lipolysisstimulated receptor, Glutathione S-transferase alpha 4, TNF receptorsuperfamily member 19, T-box 1 or putative secreted protein AccessionNo. XM_(—)620023, thereby evoking a therapeutic response in the brainendothelial cells or the cells underlying the brain endothelial cells.22. The method of claim 21, wherein the specific binding agent is anantibody to one or more of the brain endothelial markers, wherein theantibody is conjugated to the therapeutic agent and wherein thetherapeutic agent comprises a cytotoxin, chemotherapeutic reagent,radionucleotide, or combination thereof.
 23. (canceled)
 24. The methodof claim 21, wherein the brain endothelial marker protein comprises GDPDphosphodiesterase family Accession No. NM_(—)001042671, Forkhead box Q1(FOXQ1), putative transmembrane protein Accession No. NM_(—)029001,Kelch repeat and BTB (POZ) domain, Progestin and adipoQ receptor familymember V, or putative secreted protein Accession No. XM_(—)620023.
 25. Amethod of delivering a therapeutic agent to liver endothelial cells,comprising: administering a therapeutically effective amount of acomposition, wherein the composition comprises a therapeutic agent and abinding agent that specifically binds to one or more liver endothelialmarker proteins comprising deoxyribonuclease 1-like 3, LZP oncoproteininduced transcript 3, putative transmembrane protein Accession No.NM_(—)023438, CD32 15, putative G-protein coupled receptor NM_(—)033616,C-type lectin-like receptor 2, C-type lectin domain family 4 member g16, Plexin C1, Wnt9B, Accession No. AK144596, GATA-binding protein 4,MBL-associated serine protease-3, Renin binding protein, putativetransmembrane protein Accession No. NM_(—)144830, or Retinoic acidreceptor, beta, thereby evoking a therapeutic response in the liverendothelial cells.
 26. The method of claim 25, wherein the specificbinding agent is an antibody, wherein the antibody is conjugated to thetherapeutic agent, and wherein the therapeutic agent comprises acytotoxin, chemotherapeutic reagent, radionucleotide, or combinationthereof.
 27. (canceled)
 28. The method of claim 25, wherein the liverendothelial marker protein comprises oncoprotein induced transcript 3,putative transmembrane protein Accession No. NM_(—)023438, putativeG-protein coupled receptor NM_(—)033616, Plexin C1, MBL-associatedserine protease-3, Accession No. AK144596, or putative transmembraneprotein Accession No. NM_(—)144830.